var title_f10_16_10496="Tinea versicolor arm";
var content_f10_16_10496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small salmon-colored macules are evident on the arm that coalesce in some areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10496=[""].join("\n");
var outline_f10_16_10496=null;
var title_f10_16_10497="Restraint for circumcision";
var content_f10_16_10497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Baby restraint for circumcision procedures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10497=[""].join("\n");
var outline_f10_16_10497=null;
var title_f10_16_10498="Patient information: Spider bites (The Basics)";
var content_f10_16_10498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86386\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/26/6568\">",
"         Poisonous spiders",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/28/3521\">",
"          Brown recluse spider bite",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?36/44/37581\">",
"           Dangerous spiders: Where they are found and what they look like",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/51/15155\">",
"         Patient information: Insect bites and stings (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/22/18786\">",
"         Patient information: Bee and insect stings (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/44/19138\">",
"         Patient information: Fire ants (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Spider bites (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H102927729\">",
"      <span class=\"h1\">",
"       How common are spider bites?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Spider bites are very rare. Most spiders&rsquo; fangs are not strong enough to poke through your skin. Also, spiders do not usually bite unless they are crushed between you and another object.",
"     </p>",
"     <p>",
"      Most people who think a spider bit them were usually bitten by a different insect, such as a tick. Also, some skin infections can look like a spider bite.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102927746\">",
"      <span class=\"h1\">",
"       How dangerous are spider bites?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most spider bites are harmless. The poison that most spiders inject when they bite (called &ldquo;venom&rdquo;) is not toxic to people. But a few types of spiders can give painful bites. In rare cases, the bites get infected or cause other serious symptoms (",
"      <a class=\"graphic graphic_figure graphicRef86257 \" href=\"UTD.htm?6/26/6568\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Some types of dangerous spiders live only in Australia or South America. But some are found in countries all over the world, including the United States (",
"      <a class=\"graphic graphic_table graphicRef86258 \" href=\"UTD.htm?36/44/37581\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102927763\">",
"      <span class=\"h1\">",
"       What are the symptoms of a spider bite?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include a small, red, raised bump on the skin (",
"      <a class=\"graphic graphic_picture graphicRef86387 \" href=\"UTD.htm?3/28/3521\">",
"       picture 1",
"      </a>",
"      ). The bite might itch or burn.",
"     </p>",
"     <p>",
"      Some bites do not start to hurt until a few hours after the bite. The pain can range from a slight prickly feeling to very bad pain.",
"     </p>",
"     <p>",
"      In rare cases, spider bites can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Redness, swelling, and pus",
"       </li>",
"       <li>",
"        Flu-like symptoms such as feeling tired and sick to your stomach, throwing up, and fever",
"       </li>",
"       <li>",
"        Sweating",
"       </li>",
"       <li>",
"        Very bad muscle pain",
"       </li>",
"       <li>",
"        Very bad belly pain",
"       </li>",
"       <li>",
"        Dead tissue &ndash; When this happens, the center of the red bump turns a dark red, blue, or black, dries out, and forms a sore. This is called &ldquo;necrosis&rdquo; and can happen several days after a spider bite. The sore is usually about the size of a quarter but can grow larger. Most heal after a few weeks but some last for months.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102927780\">",
"      <span class=\"h1\">",
"       What should I do if a spider bites me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are bitten by a spider, you should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wash the area that was bitten with soap and water.",
"       </li>",
"       <li>",
"        Put a cold gel pack, bag of ice, or bag of frozen vegetables on the painful area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin.",
"       </li>",
"       <li>",
"        If you can, keep the bitten area raised up above the level of your heart.",
"       </li>",
"       <li>",
"        Try to figure out what type of spider bit you.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102927795\">",
"      <span class=\"h1\">",
"       Should I see a doctor or a nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See a doctor or nurse if you get any of the rare symptoms listed above.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102927812\">",
"      <span class=\"h1\">",
"       How are spider bites treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment involves cleaning the area well and offering different medicines, depending on what symptoms a person has. Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicine for pain, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;)",
"       </li>",
"       <li>",
"        Medicines to treat muscle spasms, called benzodiazepines",
"       </li>",
"       <li>",
"        A tetanus shot - Tetanus is a serious infection that causes muscle spasms and stiffness. It is caused by bacteria that can get in your body through a cut, scrape, or bite.",
"       </li>",
"       <li>",
"        Antibiotics &ndash; A doctor might prescribe these to prevent or treat an infection.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who have dead tissue because of a bite sometimes need surgery to remove the dead tissue.",
"     </p>",
"     <p>",
"      People who are bitten by a widow spider and have severe pain and muscle spasms that don&rsquo;t get better with other treatments sometimes get a special medicine called &ldquo;antivenom.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102927829\">",
"      <span class=\"h1\">",
"       What can I do to reduce the chances of getting a spider bite?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To avoid a spider bite, be extra careful in places that dangerous spiders live (",
"      <a class=\"graphic graphic_table graphicRef86258 \" href=\"UTD.htm?36/44/37581\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102927846\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=see_link\">",
"       Patient information: Insect bites and stings (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/22/18786?source=see_link\">",
"       Patient information: Bee and insect stings (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/44/19138?source=see_link\">",
"       Patient information: Fire ants (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/16/10498?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86386 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-FD0A04FE88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10498=[""].join("\n");
var outline_f10_16_10498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102927729\">",
"      How common are spider bites?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102927746\">",
"      How dangerous are spider bites?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102927763\">",
"      What are the symptoms of a spider bite?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102927780\">",
"      What should I do if a spider bites me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102927795\">",
"      Should I see a doctor or a nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102927812\">",
"      How are spider bites treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102927829\">",
"      What can I do to reduce the chances of getting a spider bite?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102927846\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86386\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/26/6568\">",
"      Poisonous spiders",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/28/3521\">",
"       Brown recluse spider bite",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_table\" href=\"UTD.htm?36/44/37581\">",
"        Dangerous spiders: Where they are found and what they look like",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/22/18786?source=related_link\">",
"      Patient information: Bee and insect stings (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/44/19138?source=related_link\">",
"      Patient information: Fire ants (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=related_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_16_10499="Fixed drug eruption penis";
var content_f10_16_10499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fixed drug eruption. An oval erosion on the glans penis occurred in this patient who was taking minocycline. According to the patient, an identical lesion appeared when he was given minocycline previously.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10499=[""].join("\n");
var outline_f10_16_10499=null;
var title_f10_16_10500="Ergoloid mesylates: Patient drug information";
var content_f10_16_10500=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ergoloid mesylates: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16596?source=see_link\">",
"     see \"Ergoloid mesylates: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hydergine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691807",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dementia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ergoloid mesylates or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the heart valve may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sublingual tablet: Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11641 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10500=[""].join("\n");
var outline_f10_16_10500=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166194\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021476\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021478\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021477\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021482\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021483\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021485\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021480\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021481\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021486\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021487\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16596?source=related_link\">",
"      Ergoloid mesylates: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_16_10501="Lovastatin and niacin: Patient drug information";
var content_f10_16_10501=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lovastatin and niacin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/1/44055?source=see_link\">",
"     see \"Lovastatin and niacin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Advicor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2935232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advicor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691638",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to slow the progress of heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body. Good cholesterol (HDL) levels rise.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702419",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lovastatin, niacin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703205",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Active liver disease, rise in liver enzymes, or ulcer disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease. Alcohol may cause more flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698093",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Taking aspirin or ibuprofen 30 minutes before taking this drug may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain in the upper, right side.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694547",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid hot drinks when it is time to take this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11401 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-2F8DE301F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10501=[""].join("\n");
var outline_f10_16_10501=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201051\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935232\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027867\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027869\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027868\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027873\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027874\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027876\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027871\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027872\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027877\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027878\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/1/44055?source=related_link\">",
"      Lovastatin and niacin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_16_10502="Clobetasol: Drug information";
var content_f10_16_10502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clobetasol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/34/13860?source=see_link\">",
"    see \"Clobetasol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/59/17333?source=see_link\">",
"    see \"Clobetasol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clobex&reg;;",
"     </li>",
"     <li>",
"      Cormax&reg;;",
"     </li>",
"     <li>",
"      Olux-E&trade;;",
"     </li>",
"     <li>",
"      Olux&reg;;",
"     </li>",
"     <li>",
"      Temovate E&reg;;",
"     </li>",
"     <li>",
"      Temovate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Clobex&reg;;",
"     </li>",
"     <li>",
"      Dermovate&reg;;",
"     </li>",
"     <li>",
"      Mylan-Clobetasol Cream;",
"     </li>",
"     <li>",
"      Mylan-Clobetasol Ointment;",
"     </li>",
"     <li>",
"      Mylan-Clobetasol Scalp Application;",
"     </li>",
"     <li>",
"      Novo-Clobetasol;",
"     </li>",
"     <li>",
"      PMS-Clobetasol;",
"     </li>",
"     <li>",
"      ratio-Clobetasol;",
"     </li>",
"     <li>",
"      Taro-Clobetasol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F152845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F152833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Discontinue when control achieved; if improvement not seen within 2 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral mucosal inflammation (unlabeled use):",
"     </b>",
"     Topical: Cream: Apply twice daily for up to 2 weeks (maximum dose: 50 g/week); discontinue application when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Steroid-responsive dermatoses:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cream, emollient cream, gel, lotion, ointment:",
"     </i>",
"     Apply twice daily for up to 2 weeks (maximum dose: 50 g/week)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Foam (Olux-E&trade;):",
"     </i>",
"     Apply to affected area twice daily for up to 2 weeks (maximum dose: 50 g/week); do not apply to face or intertriginous areas",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Steroid-responsive dermatoses of the scalp:",
"     </b>",
"     Topical: Foam (Olux&reg;), solution: Apply to affected scalp twice daily for up to 2 weeks (maximum dose: 50 g or 50 mL/week)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate plaque-type psoriasis of nonscalp areas:",
"     </b>",
"     Topical: Foam (Olux&reg;): Apply to affected area twice daily for up to 2 weeks (maximum dose: 50 g/week); do not apply to face or intertriginous areas",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Moderate-to-severe plaque-type psoriasis:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Emollient cream, lotion:",
"     </i>",
"     Apply twice daily for up to 2 weeks, has been used for up to 4 weeks when application is &lt;10% of body surface area; use with caution (maximum dose: 50 g/week)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Spray:",
"     </i>",
"     Apply by spraying directly onto affected area twice daily; should be gently rubbed into skin. Should be used for not longer than 4 weeks; treatment beyond 2 weeks should be limited to localized lesions which have not improved sufficiently. Total dose should not exceed 50 g/week or 59 mL/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Scalp psoriasis:",
"     </b>",
"     Topical: Shampoo: Apply thin film to dry scalp once daily; leave in place for 15 minutes, then add water, lather; rinse thoroughly",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F152841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/59/17333?source=see_link\">",
"      see \"Clobetasol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Discontinue when control achieved; if improvement not seen within 2 weeks, reassessment of diagnosis may be necessary. Use in children &lt;12 years is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral mucosal inflammation (unlabeled use):",
"     </b>",
"     Children &ge;12 years: Topical: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Steroid-responsive dermatoses:",
"     </b>",
"     Children &ge;12 years: Topical: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate plaque-type psoriasis of nonscalp areas:",
"     </b>",
"     Children &ge;12 years: Topical: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Moderate-to-severe plaque-type psoriasis:",
"     </b>",
"     Children &ge;16 years: Topical: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F152834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical, as propionate: 0.05% (50 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Olux-E&trade;: 0.05% (50 g, 100 g) [chlorofluorocarbon free, ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Olux&reg;: 0.05% (50 g, 100 g) [chlorofluorocarbon free; contains ethanol 60%; for scalp application]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as propionate: 0.05% (15 g, 30 g, 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temovate&reg;: 0.05% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as propionate [emollient-based]: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temovate E&reg;: 0.05% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as propionate: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temovate&reg;: 0.05% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as propionate: 0.05% (59 mL, 118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clobex&reg;: 0.05% (30 mL, 59 mL, 118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as propionate: 0.05% (15 g, 30 g, 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cormax&reg;: 0.05% (15 g [DSC], 45 g [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temovate&reg;: 0.05% (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical, as propionate: 0.05% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clobex&reg;: 0.05% (118 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as propionate [for scalp application]: 0.05% (25 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cormax&reg;: 0.05% (25 mL [DSC], 50 mL) [contains isopropyl alcohol 40%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temovate&reg;: 0.05% (50 mL) [contains isopropyl alcohol 39.3%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as propionate [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clobex&reg;: 0.05% (59 mL, 125 mL) [contains ethanol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes spray",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F152819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, gel, lotion, ointment, shampoo, solution: Apply the smallest amount that will cover affected area. Do not apply to face or intertriginous areas. Total dose should not exceed 50 g/week (or 50 mL/week of lotion, shampoo, or solution).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Foam: Turn can upside down and spray a small amount (golf-ball size) of foam into the cap or another cool surface. If the can is warm or foam is runny, place can under cold, running water. If fingers are warm, rinse with cool water and dry prior to handling (foam will melt on contact with warm skin). Massage foam into affected area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Spray: Spray directly onto affected area of skin. Gently and completely rub into skin after spraying.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F152817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term relief of inflammation of moderate-to-severe corticosteroid-responsive dermatoses (very high potency topical corticosteroid)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3196820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Clobex [U.S., Canada, and multiple international markets] may be confused with Codex brand name for",
"       <i>",
"        Saccharomyces boulardii",
"       </i>",
"       [Italy]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cloderm: Brand name for clobetasol [China, India, Malaysia, Singapore, Thailand], but also brand name for alclometasone [Indonesia]; clocortolone [U.S., Canada]; clotrimazole [Germany]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F152843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined; may depend upon formulation used, length of application, surface area covered, and the use of occlusive dressings.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Intracranial hypertension (systemic effect reported in children treated with topical corticosteroids)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal suppression, Cushing's syndrome, hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site: Burning, cracking/fissuring of the skin, dryness, erythema, folliculitis, irritation, numbness, pruritus, skin atrophy, stinging, telangiectasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glucosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Effects reported with other high-potency topical steroids: Acneiform eruptions, allergic contact dermatitis, hypertrichosis, hypopigmentation, maceration of the skin, miliaria, perioral dermatitis, secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F152822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clobetasol or any component of the formulation; viral, fungal, or tubercular skin lesions",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F152805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use in children &lt;12 years of age is not recommended. Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Application site: Do not use on the face, axillae, or groin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F152824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extensive use in pregnant women is not recommended. There are no adequate and well-controlled studies in pregnant women, however, teratogenic effects were observed in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F152836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2369143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if topical application will result in detectable quantities in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F152823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Clobetasol Propionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $40.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Temovate E External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 g): $307.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Temovate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $195.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Clobetasol Propionate Emulsion External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (50 g): $239.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Clobetasol Propionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (50 g): $169.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Olux External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (50 g): $289.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Olux-E External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (50 g): $266.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Clobetasol Propionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $47.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Temovate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 g): $270.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Clobex Spray External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (59 mL): $335.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Clobetasol Propionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (59 mL): $288.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Clobex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (59 mL): $447.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Clobetasol Propionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $40.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Temovate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $118.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Clobetasol Propionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (118 mL): $385.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Clobex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (118 mL): $596.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Clobetasol Propionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (50 mL): $53.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cormax Scalp Application External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (50 mL): $43.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Temovate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (50 mL): $233.02",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F152814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adrenal suppression with extensive/prolonged use (ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F152825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Befurine (TW);",
"     </li>",
"     <li>",
"      Betavate (KP);",
"     </li>",
"     <li>",
"      Butavate (GR);",
"     </li>",
"     <li>",
"      Clarelux Foam (GB, IE);",
"     </li>",
"     <li>",
"      Clobasone (TH);",
"     </li>",
"     <li>",
"      Clobenate (PE);",
"     </li>",
"     <li>",
"      Clobesan (ID);",
"     </li>",
"     <li>",
"      Clobesol (AR, BR, HK, IT, MX);",
"     </li>",
"     <li>",
"      Clobet (TH);",
"     </li>",
"     <li>",
"      Clobex (HK, ID, NZ, PH, SG, TW);",
"     </li>",
"     <li>",
"      Clobexpro (MX);",
"     </li>",
"     <li>",
"      Clobezan (CO, EC);",
"     </li>",
"     <li>",
"      Cloderm (AE, BH, CY, EG, HK, IQ, IR, JO, KP, KW, LB, LY, OM, QA, SA, SG, SY, TH, YE);",
"     </li>",
"     <li>",
"      Clonate (MY, PH);",
"     </li>",
"     <li>",
"      Clonovate (SG);",
"     </li>",
"     <li>",
"      Closderm (PH);",
"     </li>",
"     <li>",
"      Clovate (ES);",
"     </li>",
"     <li>",
"      Crobate (KP);",
"     </li>",
"     <li>",
"      Decloban (ES);",
"     </li>",
"     <li>",
"      Delor (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Derbisol (KP);",
"     </li>",
"     <li>",
"      Dermatovate (MX);",
"     </li>",
"     <li>",
"      Dermol (NZ);",
"     </li>",
"     <li>",
"      Dermosol (KP);",
"     </li>",
"     <li>",
"      Dermoval (FR);",
"     </li>",
"     <li>",
"      Dermovat (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Dermovate (AE, AT, BB, BD, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CN, CO, CY, CZ, EC, EE, EG, ET, GB, GH, GM, GN, GT, GY, HK, HN, IE, IL, IQ, IR, JM, JO, JP, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RU, SA, SC, SD, SG, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Dermoxin (DE);",
"     </li>",
"     <li>",
"      Dhabesol (HK, KP, MY);",
"     </li>",
"     <li>",
"      Dovate (ZA);",
"     </li>",
"     <li>",
"      Etrivex (GB);",
"     </li>",
"     <li>",
"      Eurobetsol (HK);",
"     </li>",
"     <li>",
"      Forderm (ID);",
"     </li>",
"     <li>",
"      Glevate (PH);",
"     </li>",
"     <li>",
"      Karison Creme (DE);",
"     </li>",
"     <li>",
"      Karison Salbe (DE);",
"     </li>",
"     <li>",
"      Kloderma (ID);",
"     </li>",
"     <li>",
"      Lobate (IN);",
"     </li>",
"     <li>",
"      Lobesol (MY);",
"     </li>",
"     <li>",
"      Lobevat (CR, DO, GT, HN, MX, NI, PA, SV);",
"     </li>",
"     <li>",
"      Lotasbat (ID);",
"     </li>",
"     <li>",
"      Medodermone (SG);",
"     </li>",
"     <li>",
"      P-Vate (TH);",
"     </li>",
"     <li>",
"      Pentasol (CO);",
"     </li>",
"     <li>",
"      Probelin (PH);",
"     </li>",
"     <li>",
"      Rubocort (GR);",
"     </li>",
"     <li>",
"      S.Z. (TW);",
"     </li>",
"     <li>",
"      Stivate (TH);",
"     </li>",
"     <li>",
"      Tempovate (ID);",
"     </li>",
"     <li>",
"      Tenovate (IN);",
"     </li>",
"     <li>",
"      Topifort (IN);",
"     </li>",
"     <li>",
"      Uniderm (HK, KP, TH);",
"     </li>",
"     <li>",
"      Univate (MY);",
"     </li>",
"     <li>",
"      Yihfu (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F152804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates the synthesis of enzymes needed to decrease inflammation, suppress mitotic activity, and cause vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F152821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Percutaneous absorption is variable and dependent upon many factors including vehicle used, integrity of epidermis, dose, and use of occlusive dressings",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/16/10502/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9276 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10502=[""].join("\n");
var outline_f10_16_10502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152831\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152832\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152845\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152833\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152841\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152834\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152816\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152801\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152819\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152817\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3196820\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152843\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152822\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152805\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299062\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152809\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152811\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152824\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152836\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2369143\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152823\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152814\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152825\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152804\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152821\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9276\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9276|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/34/13860?source=related_link\">",
"      Clobetasol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/59/17333?source=related_link\">",
"      Clobetasol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_16_10503="Chronic thromboembolic pulmonary hypertension: Surgical treatment";
var content_f10_16_10503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic thromboembolic pulmonary hypertension: Surgical treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/16/10503/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/16/10503/contributors\">",
"     Peter F Fedullo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/16/10503/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/16/10503/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/16/10503/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/16/10503/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/16/10503/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the only definitive therapy for chronic thromboembolic pulmonary hypertension (CTEPH), with pulmonary thromboendarterectomy being the surgical procedure of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Preparation for pulmonary thromboendarterectomy, the procedure itself, postoperative management, and outcomes following pulmonary thromboendarterectomy are reviewed here. The general approach to the treatment of CTEPH is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34293?source=see_link\">",
"     \"Overview of the treatment of chronic thromboembolic pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR PULMONARY THROMBOENDARTERECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the only potentially curative therapy for chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary thromboendarterectomy is the surgical procedure of choice. The decision to proceed to pulmonary thromboendarterectomy is based upon four criteria: the surgical accessibility of the thrombi; the presence of hemodynamic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventilatory impairment; the impact of the patient&rsquo;s comorbidities on the risks of the surgery; and the willingness and motivation of the patient to undergo surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/1\">",
"     1",
"    </a>",
"    ]. Evaluation for pulmonary thromboendarterectomy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34293?source=see_link&amp;anchor=H19764309#H19764309\">",
"     \"Overview of the treatment of chronic thromboembolic pulmonary hypertension\", section on 'Evaluation for pulmonary thromboendarterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREPARATION FOR PULMONARY THROMBOENDARTERECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inferior vena caval filter is routinely placed prior to surgery, unless an obvious non-leg or non-pelvic source was the cause of the pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/1\">",
"     1",
"    </a>",
"    ]. This is generally done several days prior to surgery, in order to avoid bleeding complications at the insertion site during the perioperative period. Percutaneous transfemoral vein insertion is preferred. The purpose of inferior vena caval filter insertion is to protect patients from recurrent pulmonary emboli both during the high-risk perioperative period and over the long-term, in the event that thromboprophylaxis or anticoagulant therapy has to be discontinued due to bleeding complications or the need for other surgical procedures.",
"   </p>",
"   <p>",
"    Coronary angiography is routinely performed prior to surgery in patients who are at risk for coronary artery disease. This is usually done at the same time as right heart catheterization, pulmonary angiography, and pulmonary angioscopy. Coronary artery bypass grafting can be performed during the same operation as the pulmonary thromboendarterectomy, if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PULMONARY THROMBOENDARTERECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary thromboendarterectomy involves median sternotomy, cardiopulmonary bypass, and periods of hypothermic circulatory arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/1,4-7\">",
"     1,4-7",
"    </a>",
"    ]. The median sternotomy allows access to the pulmonary arteries, assures more complete removal of the chronically obstructing material, and decreases the likelihood that bronchial artery collateral flow will be disrupted. &nbsp;Cardiopulmonary bypass with periods of hypothermic circulatory arrest provides the bloodless operative field essential for meticulous lobar and segmental dissections.",
"   </p>",
"   <p>",
"    Periods of circulatory arrest are limited to 20-minute intervals (an entire unilateral endarterectomy can usually be accomplished within this time by an experienced surgeon). After each period of circulatory arrest, reperfusion is carried out until either the pulmonary venous saturations reach 90 percent or at least 10 minutes has passed. At the completion of the bilateral pulmonary endarterectomy, circulation is reestablished and the patient is rewarmed. The atrial septum is routinely inspected, since an atrial septal defect or persistent foramen ovale is identified and repaired in approximately 25 percent of cases. Additional procedures, such as coronary bypass grafting or valve replacement, are performed during the rewarming period if they are required.",
"   </p>",
"   <p>",
"    Several alternative techniques have been explored in an effort to reduce the neurological complications of hypothermia and circulatory arrest, but none has proven superior to the traditional technique [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/1\">",
"     1",
"    </a>",
"    ]. The alternative techniques include the use of moderate rather than deep hypothermia, aortic bronchial artery occlusion with a balloon catheter, antegrade cerebral artery perfusion with and without total circulatory arrest, and the application of negative pressure in the left ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be emphasized that pulmonary thromboendarterectomy bears no resemblance to acute pulmonary embolectomy. The neointima in chronic thromboembolic disease is not easily recognizable as chronic thromboemboli and, thus, a true endarterectomy is necessary to restore pulmonary arterial patency (",
"    <a class=\"graphic graphic_picture graphicRef78850 \" href=\"UTD.htm?37/51/38708\">",
"     picture 1",
"    </a>",
"    ). This requires careful dissection of chronic endothelialized material from the native intima. There are several levels within the vessel where an endarterectomy plane can be established, but only one will strip easily away from the underlying media. Establishing the correct plane is essential. A plane that is too deep will result in perforation of the vessel, while a plane that is too superficial will not result in an adequate endarterectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vigilant postoperative monitoring and management is necessary because the postoperative course can be complex [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/11\">",
"     11",
"    </a>",
"    ]. Early management should focus on minimizing systemic oxygen consumption, optimizing right ventricular preload, and providing inotropic support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4793743\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic thromboembolic pulmonary hypertension (CTEPH) are maintained on lifelong anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/12\">",
"     12",
"    </a>",
"    ]. This therapy is held preoperatively and then resumed postoperatively. &nbsp;For the majority of patients, thromboprophylaxis (eg, subcutaneous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [UFH] at 5000 units every eight to twelve hours) is initiated on the evening of the surgical procedure, once the mediastinal output has decreased to approximately 30",
"    <span class=\"nowrap\">",
"     ml/hr.",
"    </span>",
"    However, for those patients who are at particularly high risk for thromboembolic recurrence (eg, patients with a lupus anticoagulant or antiphospholipid antibody), full dose anticoagulation using intravenous UFH is initiated with the goal aPTT in a low therapeutic range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4793786\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo pulmonary thromboendarterectomy may experience complications that are common to other types of thoracic surgery (eg, arrhythmias, atelectasis, wound infection, pericardial effusions, and delirium). They may also experience two unique complications that can significantly impair gas exchange: pulmonary artery steal and reperfusion pulmonary edema (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11434?source=see_link\">",
"     \"Overview of the management of postoperative pulmonary complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1664046\">",
"    <span class=\"h3\">",
"     Pulmonary artery steal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary artery steal, which occurs in approximately 70 percent of patients undergoing thromboendarterectomy, refers to the postoperative redistribution of pulmonary arterial blood flow from well perfused segments into the newly endarterectomized segments, with subsequent ventilation-perfusion mismatching and hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/13\">",
"     13",
"    </a>",
"    ]. Although incompletely understood, this is probably related to differential resistances within the pulmonary vascular bed following thromboendarterectomy. Treatment is supportive (ie, supplemental oxygen, mechanical ventilation). Pulmonary vascular steal resolves in most patients, with supplemental oxygen no longer required within two weeks of hospital discharge in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Reperfusion pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reperfusion pulmonary edema, which occurs in approximately 30 percent of patients undergoing thromboendarterectomy, is a type of high-permeability (ie, non-cardiogenic) pulmonary edema that typically occurs in areas of the lung from which proximal thromboemboli were removed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. It may appear up to 72 hours after surgery and varies in severity. Its manifestations range from mild postoperative hypoxemia to acute, hemorrhagic pulmonary edema resulting in death.",
"   </p>",
"   <p>",
"    Management of reperfusion edema following pulmonary thromboendarterectomy is supportive (ie, supplemental oxygen, mechanical ventilation), although case reports and a small case series suggest that inhaled nitric oxide may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. It is hypothesized that the inhaled nitric oxide vasodilates the blood vessels that perfuse the well-ventilated alveoli, thereby redirecting blood flow to the well perfused alveoli, improving ventilation-perfusion matching, and reducing the severity of hypoxemia. The median ICU length of stay is four days, with a postoperative length of stay of 14 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=see_link&amp;anchor=H5274368#H5274368\">",
"     \"Novel therapies for the acute respiratory distress syndrome\", section on 'Nitric oxide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reperfusion pulmonary edema and pulmonary artery steal can occur together. In this situation, the hypoxemia may be particularly profound because pulmonary blood flow is directed towards edematous, noncompliant areas of lung that contribute poorly to gas-exchange.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3756882\">",
"    <span class=\"h2\">",
"     Residual pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Residual pulmonary hypertension with persistent functional impairment may be an indication for medical therapy, as discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14837?source=see_link\">",
"     \"Chronic thromboembolic pulmonary hypertension: Medical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Repeat thromboendarterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat pulmonary thromboendarterectomy has been performed successfully in patients who had previously undergone a unilateral thromboendarterectomy procedure or who experienced recurrent pulmonary vascular obstruction. The morbidity and mortality of the second surgery is comparable to the primary procedure, but the improvement in hemodynamics is typically less impressive [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OUTCOMES FOLLOWING PULMONARY THROMBOENDARTERECTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Perioperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative mortality among patients undergoing pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension (CTEPH) has decreased according to several observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. In a study of 500 such patients, perioperative mortality was 16 percent before 1990, 7 percent between 1990 and 1999, and 4 percent between 1998 and 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/22\">",
"     22",
"    </a>",
"    ]. A subsequent study from an international registry reported an in-hospital postoperative mortality rate of 4.7 percent between 2007 and 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/23\">",
"     23",
"    </a>",
"    ]. Among low risk patients, a perioperative mortality rate of only 1.3 percent has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/6\">",
"     6",
"    </a>",
"    ]. Reperfusion pulmonary edema and right ventricular failure due to residual pulmonary hypertension are the most common causes of death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/1\">",
"     1",
"    </a>",
"    ]. Cardiac arrest, multiorgan failure, uncontrollable mediastinal bleeding, sepsis syndrome, and massive pulmonary hemorrhage also occur.",
"   </p>",
"   <p>",
"    Hemodynamic improvement may be dramatic and immediate following thromboendarterectomy, with marked reductions in pulmonary artery pressures and pulmonary vascular resistance (",
"    <a class=\"graphic graphic_table graphicRef81069 \" href=\"UTD.htm?15/15/15611\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/1,24,25\">",
"     1,24,25",
"    </a>",
"    ]. In one study, the mean reduction in pulmonary vascular resistance was nearly 70 percent and a pulmonary vascular resistance in the range of 200 to 350 dyne",
"    <span class=\"nowrap\">",
"     seconds/cm",
"     <sup>",
"      5",
"     </sup>",
"    </span>",
"    was frequently achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/26\">",
"     26",
"    </a>",
"    ]. The hemodynamic improvement is associated with improvement of symptoms and physical signs. Echocardiography demonstrates a decrease in right atrial and right ventricular chamber size, normalization of the interventricular septum, and decrease or resolution of tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Long-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality due to CTEPH is low among patients who survive three months post-thromboendarterectomy. In an observational study that followed 137 such survivors, only six patients (4 percent) died from CTEPH-related causes during the four year follow-up period [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/31\">",
"     31",
"    </a>",
"    ]. A similar study demonstrated one- and three-year mortality rates of 1 and 6 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/20\">",
"     20",
"    </a>",
"    ]. Less than 0.5 percent of all patients who have undergone a pulmonary thromboendarterectomy develop recurrent thromboembolic disease that requires a repeat pulmonary thromboendarterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/21\">",
"     21",
"    </a>",
"    ]. Many of the individuals who develop recurrent thromboembolic disease have had inadequate management of their anticoagulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    had not undergone placement of an inferior vena cava filter.",
"   </p>",
"   <p>",
"    Hemodynamic and symptomatic improvement generally persist following surgery according to studies that have followed patients for up to 12 months (",
"    <a class=\"graphic graphic_table graphicRef60924 \" href=\"UTD.htm?27/34/28203\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Long-term improvement is likely multifactorial: reduced right ventricular afterload due to improvement of the pulmonary hypertension, resolution of postoperative anemia and deconditioning, and improved ventilation-perfusion matching as postoperative pulmonary artery steal resolves. Most patients are New York Heart Association (NYHA) functional Class III or IV preoperatively and improve to NYHA Class I or II postoperatively (",
"    <a class=\"graphic graphic_table graphicRef52486 \" href=\"UTD.htm?8/45/8923\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    ). Many patients will resume normal activity, including employment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary thromboendarterectomy also appears to have a lasting impact on peripheral oxygen extraction and cardiac performance. This was demonstrated by a study in which serial cardiopulmonary exercise testing was performed on 20 patients who had undergone pulmonary thromboendarterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/33\">",
"     33",
"    </a>",
"    ]. Two distinct changes were noted. First, there was ongoing improvement of peak oxygen uptake. Second, ventilatory efficiency and exercise capacity improved, reaching a plateau one to six months after surgery. The increased ventilatory efficiency was a consequence of a decreased dead space to tidal volume ratio",
"    <span class=\"nowrap\">",
"     (VD/VT),",
"    </span>",
"    as measured by the",
"    <span class=\"nowrap\">",
"     VE/VCO2",
"    </span>",
"    slope during exercise. While improvement of the ventilatory efficiency correlated with the acute decrease in pulmonary vascular resistance (PVR), improvement of the exercise capacity did not. General principles of cardiopulmonary exercise testing are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33398?source=see_link\">",
"     \"Functional exercise testing: Ventilatory gas analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent pulmonary hypertension occurs in 5 to 35 percent of patients who undergo pulmonary thromboendarterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/20,34-36\">",
"     20,34-36",
"    </a>",
"    ], likely due to unanticipated distal (ie, surgically inaccessible) thromboemboli or irreversible vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/1\">",
"     1",
"    </a>",
"    ]. The variation of the estimates likely reflects the use of different definitions of persistent pulmonary hypertension. It is possible for patients with persistent pulmonary hypertension to achieve functional improvement and a survival equivalent those who do not have persistent pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/36\">",
"     36",
"    </a>",
"    ]. This may indicate that it is the size of the reduction in pulmonary vascular resistance that matters, rather than the final pulmonary vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10503/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1663888\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery is the only definitive therapy for chronic thromboembolic pulmonary hypertension (CTEPH), with pulmonary thromboendarterectomy being the surgical procedure of choice. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to proceed to pulmonary thromboendarterectomy is based upon four criteria: the surgical accessibility of the thrombi; the presence of hemodynamic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ventilatory impairment; the impact of the patient&rsquo;s comorbidities on the risks of the surgery; and the willingness and motivation of the patient to undergo surgery. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for pulmonary thromboendarterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CTEPH who are scheduled to undergo pulmonary thromboendarterectomy, we suggest placement of an inferior vena caval filter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An exception is when an obvious non-leg or non-pelvic source was the cause of the pulmonary embolism. Inferior vena caval filter insertion is generally done several days prior to surgery, in order to avoid bleeding complications at the insertion site during the perioperative period. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Preparation for pulmonary thromboendarterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary thromboendarterectomy involves median sternotomy, cardiopulmonary bypass, and periods of hypothermic circulatory arrest. Alternative techniques have been explored, but none has proven superior to the traditional technique. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pulmonary thromboendarterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who undergo pulmonary thromboendarterectomy may experience complications that are common to other types of thoracic surgery (eg, arrhythmias, atelectasis, wound infection, pericardial effusions, and delirium), as well as two unique complications that can significantly impair gas exchange: pulmonary artery steal and reperfusion pulmonary edema. The unique complications are typically self-limited and treated supportively. (See",
"      <a class=\"local\" href=\"#H4793786\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The beneficial effects of pulmonary thromboendarterectomy may be immediate, dramatic, and sustained. These include improved exercise capacity, decreased pulmonary vascular resistance and pulmonary artery pressure, and, probably, decreased mortality. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Outcomes following pulmonary thromboendarterectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/1\">",
"      Fedullo P, Kerr KM, Kim NH, Auger WR. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2011; 183:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/2\">",
"      Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2011; 364:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/3\">",
"      Thistlethwaite PA, Auger WR, Madani MM, et al. Pulmonary thromboendarterectomy combined with other cardiac operations: indications, surgical approach, and outcome. Ann Thorac Surg 2001; 72:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/4\">",
"      Jamieson SW, Auger WR, Fedullo PF, et al. Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. J Thorac Cardiovasc Surg 1993; 106:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/5\">",
"      Zund G, Pr&ecirc;tre R, Niederh&auml;user U, et al. Improved exposure of the pulmonary arteries for thromboendarterectomy. Ann Thorac Surg 1998; 66:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/6\">",
"      Thistlethwaite PA, Kaneko K, Madani MM, Jamieson SW. Technique and outcomes of pulmonary endarterectomy surgery. Ann Thorac Cardiovasc Surg 2008; 14:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/7\">",
"      Madani MM, Jamieson SW. Technical advances of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Semin Thorac Cardiovasc Surg 2006; 18:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/8\">",
"      Hagl C, Khaladj N, Peters T, et al. Technical advances of pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Eur J Cardiothorac Surg 2003; 23:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/9\">",
"      Thomson B, Tsui SS, Dunning J, et al. Pulmonary endarterectomy is possible and effective without the use of complete circulatory arrest--the UK experience in over 150 patients. Eur J Cardiothorac Surg 2008; 33:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/10\">",
"      Mikus PM, Mikus E, Mart&igrave;n-Su&agrave;rez S, et al. Pulmonary endarterectomy: an alternative to circulatory arrest and deep hypothermia: mid-term results. Eur J Cardiothorac Surg 2008; 34:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/11\">",
"      Fedullo PF, Auger WR, Dembitsky WP. Postoperative management of the patient undergoing pulmonary thromboendarterectomy. Semin Thorac Cardiovasc Surg 1999; 11:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/12\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/13\">",
"      Olman MA, Auger WR, Fedullo PF, Moser KM. Pulmonary vascular steal in chronic thromboembolic pulmonary hypertension. Chest 1990; 98:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/14\">",
"      Moser KM, Metersky ML, Auger WR, Fedullo PF. Resolution of vascular steal after pulmonary thromboendarterectomy. Chest 1993; 104:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/15\">",
"      Levinson RM, Shure D, Moser KM. Reperfusion pulmonary edema after pulmonary artery thromboendarterectomy. Am Rev Respir Dis 1986; 134:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/16\">",
"      Lee KC, Cho YL, Lee SY. Reperfusion pulmonary edema after pulmonary endarterectomy. Acta Anaesthesiol Sin 2001; 39:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/17\">",
"      G&aring;rdeb&auml;ck M, Larsen FF, R&aring;degran K. Nitric oxide improves hypoxaemia following reperfusion oedema after pulmonary thromboendarterectomy. Br J Anaesth 1995; 75:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/18\">",
"      Imanaka H, Miyano H, Takeuchi M, et al. Effects of nitric oxide inhalation after pulmonary thromboendarterectomy for chronic pulmonary thromboembolism. Chest 2000; 118:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/19\">",
"      Pinelli G, Mertes PM, Carteaux JP, et al. Inhaled nitric oxide as an adjunct to pulmonary thromboendarterectomy. Ann Thorac Surg 1996; 61:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/20\">",
"      Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008; 177:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/21\">",
"      Mo M, Kapelanski DP, Mitruka SN, et al. Reoperative pulmonary thromboendarterectomy. Ann Thorac Surg 1999; 68:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/22\">",
"      Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003; 76:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/23\">",
"      Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/24\">",
"      Moser KM, Daily PO, Peterson K, et al. Thromboendarterectomy for chronic, major-vessel thromboembolic pulmonary hypertension. Immediate and long-term results in 42 patients. Ann Intern Med 1987; 107:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/25\">",
"      Moser KM, Spragg RG, Utley J, Daily PO. Chronic thrombotic obstruction of major pulmonary arteries. Results of thromboendarterectomy in 15 patients. Ann Intern Med 1983; 99:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/26\">",
"      Auger WR, Fedullo PF. Chronic thromboembolic pulmonary hypertension. Semin Respir Crit Care Med 2009; 30:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/27\">",
"      Sadeghi HM, Kimura BJ, Raisinghani A, et al. Does lowering pulmonary arterial pressure eliminate severe functional tricuspid regurgitation? Insights from pulmonary thromboendarterectomy. J Am Coll Cardiol 2004; 44:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/28\">",
"      Thistlethwaite PA, Jamieson SW. Tricuspid valvular disease in the patient with chronic pulmonary thromboembolic disease. Curr Opin Cardiol 2003; 18:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/29\">",
"      Dittrich HC, Nicod PH, Chow LC, et al. Early changes of right heart geometry after pulmonary thromboendarterectomy. J Am Coll Cardiol 1988; 11:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/30\">",
"      Casaclang-Verzosa G, McCully RB, Oh JK, et al. Effects of pulmonary thromboendarterectomy on right-sided echocardiographic parameters in patients with chronic thromboembolic pulmonary hypertension. Mayo Clin Proc 2006; 81:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/31\">",
"      Corsico AG, D'Armini AM, Cerveri I, et al. Long-term outcome after pulmonary endarterectomy. Am J Respir Crit Care Med 2008; 178:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/32\">",
"      Archibald CJ, Auger WR, Fedullo PF, et al. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med 1999; 160:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/33\">",
"      Iwase T, Nagaya N, Ando M, et al. Acute and chronic effects of surgical thromboendarterectomy on exercise capacity and ventilatory efficiency in patients with chronic thromboembolic pulmonary hypertension. Heart 2001; 86:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/34\">",
"      Bonderman D, Skoro-Sajer N, Jakowitsch J, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007; 115:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/35\">",
"      Thistlethwaite PA, Kemp A, Du L, et al. Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2006; 131:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10503/abstract/36\">",
"      Freed DH, Thomson BM, Berman M, et al. Survival after pulmonary thromboendarterectomy: effect of residual pulmonary hypertension. J Thorac Cardiovasc Surg 2011; 141:383.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8255 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10503=[""].join("\n");
var outline_f10_16_10503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1663888\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR PULMONARY THROMBOENDARTERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREPARATION FOR PULMONARY THROMBOENDARTERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PULMONARY THROMBOENDARTERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4793743\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4793786\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1664046\">",
"      - Pulmonary artery steal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Reperfusion pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3756882\">",
"      Residual pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Repeat thromboendarterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OUTCOMES FOLLOWING PULMONARY THROMBOENDARTERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Perioperative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Long-term",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1663888\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8255\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8255|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/51/38708\" title=\"picture 1\">",
"      Chronic pulm thromboemboli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8255|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/15/15611\" title=\"table 1\">",
"      Hemodyn pulm thromboend I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/34/28203\" title=\"table 2\">",
"      Hemodyn pulm thromboend II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/45/8923\" title=\"table 3\">",
"      NYHA alter pulm thromboend",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 4\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14837?source=related_link\">",
"      Chronic thromboembolic pulmonary hypertension: Medical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33398?source=related_link\">",
"      Functional exercise testing: Ventilatory gas analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29402?source=related_link\">",
"      Management of cardiac risk for noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=related_link\">",
"      Novel therapies for the acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11434?source=related_link\">",
"      Overview of the management of postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34293?source=related_link\">",
"      Overview of the treatment of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_16_10504="Carnitine cycle";
var content_f10_16_10504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Carnitine cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 565px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram illustrating the carnitine cycle. The mitochondrial membrane is not permeable to long-chain fatty acids; a multi-step process is therefore required for these compounds to be used by mitochondria. In the muscle cytoplasm, long-chain fatty acids are first activated by long-chain acyl-CoA synthetase (ACS) to their CoA thioesters. The CoA thioesters are subsequently linked with carnitine by the enzyme carnitine palmitoyltransferase I (CPT I) located on the inner side of the outer mitochondrial membrane. The acylcarnitine form of the long-chain fatty acid, palmitoylcarnitine, is then transferred across the inner mitochondrial membrane by carnitine:acylcarnitine translocase. Once in the mitochondrial matrix, it is converted back to free acyl-CoA derivative and carnitine by carnitine palmitoyltransferase II (CPT II) on the inner side of the inner mitochondrial membrane. Once carnitine is released, the long-chain acyl-CoA derivative enters the beta-oxidation pathway. With every complete cycle, a two-carbon fragment is cleaved and an acetyl-CoA molecule is released.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10504=[""].join("\n");
var outline_f10_16_10504=null;
var title_f10_16_10505="Acute respiratory distress syndrome: Clinical features and diagnosis";
var content_f10_16_10505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute respiratory distress syndrome: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/16/10505/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/16/10505/contributors\">",
"     John Hansen-Flaschen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/16/10505/contributors\">",
"     Mark D Siegel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/16/10505/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/16/10505/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/16/10505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/16/10505/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/16/10505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A distinct type of hypoxemic respiratory failure characterized by acute abnormality of both lungs was first recognized during the 1960s. Military clinicians working in surgical hospitals in Vietnam called it shock lung, while civilian clinicians referred to it as adult respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent recognition that individuals of any age could be afflicted led to the current term, acute respiratory distress syndrome (ARDS).",
"   </p>",
"   <p>",
"    ARDS is an acute, diffuse, inflammatory lung injury that leads to increased pulmonary vascular permeability, increased lung weight, and a loss of aerated tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinical hallmarks of ARDS are hypoxemia and bilateral radiographic opacities, while the pathological hallmark is diffuse alveolar damage (ie, alveolar edema with or without focal hemorrhage, acute inflammation of the alveolar walls, and hyaline membranes).",
"   </p>",
"   <p>",
"    ARDS is associated with a variety of risk factors and etiologies. These conditions are grouped together under the term ARDS because the clinical, physiological features, pathological features, and management are similar regardless of the inciting event.",
"   </p>",
"   <p>",
"    The clinical presentation, course, diagnostic evaluation, and diagnostic criteria of ARDS are reviewed here. The epidemiology, pathogenesis, etiology, and management of ARDS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=see_link\">",
"     \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4871?source=see_link\">",
"     \"Acute respiratory distress syndrome: Prognosis and outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=see_link\">",
"     \"Novel therapies for the acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10171119\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of ARDS usually appear within 6 to 72 hours of an inciting event and worsen rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients typically present with dyspnea, cyanosis (ie, hypoxemia), and diffuse crackles. Respiratory distress is usually evident, including tachypnea, tachycardia, diaphoresis, and use of accessory muscles of respiration. A cough and chest pain may also exist.",
"   </p>",
"   <p>",
"    Arterial blood gases reveal hypoxemia, which is often accompanied by acute respiratory alkalosis and an elevated alveolar-arterial oxygen gradient (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?30/51/31539?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). High concentrations of supplemental oxygen are generally required to maintain adequate oxygenation.",
"   </p>",
"   <p>",
"    The initial chest radiograph typically has bilateral alveolar infiltrates (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53014 \" href=\"UTD.htm?13/38/13920\">",
"     image 1",
"    </a>",
"    ), while computed tomography (CT) usually reveals widespread patchy or coalescent airspace opacities that are usually more apparent in the dependent lung zones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71931 \" href=\"UTD.htm?38/43/39601\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The infiltrates do not have to be diffuse or severe, as bilateral infiltrates of any severity are sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical findings related to the precipitant may also exist at presentation. As an example, in patients with ARDS due to sepsis, there may be fever, hypotension, leukocytosis, lactic acidosis, and disseminated intravascular coagulation (DIC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first several days of ARDS are characterized by hypoxemia requiring a moderate to high concentration of inspired oxygen. The bilateral alveolar infiltrates and diffuse crackles are persistent during this period and patients may be tenuous due to severe hypoxemia.",
"   </p>",
"   <p>",
"    Most patients who survive this initial course begin to exhibit better oxygenation and decreasing alveolar infiltrates over the next several days. This may permit the amount of ventilatory support to be decreased and weaning to begin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21112?source=see_link\">",
"     \"Weaning from mechanical ventilation: Readiness testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14423?source=see_link\">",
"     \"Methods of weaning from mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients, however, have persistent, severe hypoxemia and remain ventilator-dependent. Pulmonary proliferative changes and fibrosis may progressively replace the pathological findings of diffuse alveolar damage as early as ten days after the onset of the respiratory failure. The fibroproliferative phase of ARDS is characterized radiographically by progression from airspace opacification to a more coarsely reticular pattern of lung infiltration. These changes within the lung parenchyma are often accompanied by persistent hypoxemia, low lung compliance, high dead space, and sometimes by progressive pulmonary hypertension. The course may become dominated by persistent ventilator dependence and various complications.",
"   </p>",
"   <p>",
"    The lungs of patients who survive the fibroproliferative phase enter into an extended subsequent phase of resolution and repair. Hypoxemia and pulmonary infiltrates gradually improve over weeks to months. Cardiopulmonary function often returns to near baseline levels by 6 months or longer after the initial lung injury. However, many survivors of severe ARDS are left with persistent cognitive impairment, emotional disturbances, and residual muscle weakness resulting in substantially reduced quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4871?source=see_link\">",
"     \"Acute respiratory distress syndrome: Prognosis and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ARDS are at high risk for complications. Some complications are related to mechanical ventilation (eg, pulmonary barotrauma, nosocomial pneumonia), while others are related to critical illness and being in the intensive care unit (eg, delirium, deep venous thrombosis, gastrointestinal bleeding due to stress ulceration, and catheter-related infections).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Barotrauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ARDS are predisposed to pulmonary barotrauma due to the physical stress of positive pressure mechanical ventilation on acutely damaged alveolar membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It was previously common for patients with ARDS to develop single or multiple, sequential, loculated pneumothoraces. Clinical experience suggests that such complications are less common now that low tidal volume ventilation has become widespread. This is supported by the observations that (a) low tidal volume ventilation reduces the plateau airway pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/12\">",
"     12",
"    </a>",
"    ] and (b) a lower plateau airway pressure is associated with a lower incidence of pulmonary barotrauma. The latter was illustrated by a systematic review of 14 clinical studies (2270 patients with ARDS) that found a strong correlation between pulmonary barotrauma and a plateau airway pressure &gt;35 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographically apparent barotrauma sometimes occurs despite an appropriate mechanical ventilation strategy and can contribute to death in patients with other risk factors for a poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/14\">",
"     14",
"    </a>",
"    ]. The pathogenesis, risk factors, prevention, presentation, diagnosis, management, and prognosis of pulmonary barotrauma are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARDS and other forms of acute respiratory failure are commonly complicated by delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/15\">",
"     15",
"    </a>",
"    ]. Deep sedation and pharmacologically-induced neuromuscular blockade are often used to treat agitated delirium. While these interventions may contribute to adverse outcomes such as prolongation of mechanical ventilation, persistent muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], and long-term impairments in cognition and short-term memory among survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/18\">",
"     18",
"    </a>",
"    ], they may also optimize mechanical ventilation (ie, mitigate derecruitment associated with patient-ventilator dyssynchrony) and prevent dislodgment of the endotracheal tube and vascular catheters. One trial found that neuromuscular blockade was associated with improved survival in patients with severe ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of sedatives and neuromuscular blocking agents in critically ill patients is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=see_link\">",
"     \"Use of neuromuscular blocking medications in critically ill patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Nosocomial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial pneumonia is an important cause of morbidity and mortality in patients who have ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4871?source=see_link&amp;anchor=H3#H3\">",
"     \"Acute respiratory distress syndrome: Prognosis and outcomes\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of nosocomial pneumonia among patients with ARDS is uncertain because the similar symptoms, signs, and radiographic findings make it difficult to distinguish pneumonia from the underlying ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. The difficulty identifying pneumonia in patients with ARDS was illustrated by an autopsy study that found pneumonia in 58 percent of patients with ARDS, although pneumonia was suspected antemortem in only 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/25\">",
"     25",
"    </a>",
"    ]. Twenty percent of patients thought to have pneumonia did not have histologic evidence of pneumonia.",
"   </p>",
"   <p>",
"    Despite the uncertainty about the incidence of nosocomial pneumonia among patients with ARDS, there is evidence that nosocomial pneumonia is more common among patients who are mechanically ventilated for ARDS than among patients who are mechanically ventilated for other reasons. This was demonstrated by an observational study of 243 consecutive patients who required mechanical ventilation, which found that patients with ARDS were significantly more likely to develop nosocomial pneumonia than patients without ARDS (55 versus 28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/26\">",
"     26",
"    </a>",
"    ]. A possible explanation for these findings is that patients with ARDS required a longer duration of mechanical ventilation.",
"   </p>",
"   <p>",
"    The diagnosis, prevention, and management of nosocomial pneumonia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=see_link\">",
"     \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications that frequently occur during the hospital course of patients with ARDS include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deep venous thrombosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"       \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding due to stress ulceration (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"       \"Stress ulcer prophylaxis in the intensive care unit\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Poor nutrition (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"       \"Nutrition support in critically ill patients: An overview\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Catheter-related infections (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link\">",
"       \"Diagnosis of intravascular catheter-related infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link\">",
"       \"Prevention of intravascular catheter-related infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link\">",
"       \"Treatment of intravascular catheter-related infections\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation is aimed at identifying specific causes of ARDS that are amenable to treatment and excluding other conditions that also present with acute hypoxemia, bilateral alveolar infiltrates, and respiratory distress.",
"    <strong>",
"    </strong>",
"    Because the current international consensus definition of ARDS (see",
"    <a class=\"local\" href=\"#H10171195\">",
"     'Diagnostic criteria'",
"    </a>",
"    below) specifies no criteria relating to the underlying etiology of acute bilateral inflammatory",
"    <em>",
"    </em>",
"    lung injury, some uncertainty remains with respect to which conditions should or should not be included under the ARDS diagnostic umbrella. Generally included are disorders that are known to cause diffuse alveolar damage and have the potential to resolve over time. Thus, viral or diffuse bacterial pneumonia and acute inhalational injuries are included, whereas eosinophilic pneumonia",
"    <strong>",
"    </strong>",
"    and diffuse alveolar hemorrhage associated with collagen vascular diseases are not. Cardiogenic pulmonary edema is the primary alternative that needs to be excluded because it is common and can be clinically indistinguishable from ARDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Excluding cardiogenic pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;An absence of cardiac exam abnormalities (eg, an S3 or S4 gallop, new or changed murmur), elevated right-sided filling pressures (eg, elevated jugular venous pressure), and certain radiographic abnormalities (eg, pulmonary venous congestion, Kerley B lines, cardiomegaly, and pleural effusions), helps distinguish ARDS from cardiogenic pulmonary edema. Several additional diagnostic tests may also be helpful, including measurement of plasma brain natriuretic peptide levels, echocardiography, and right heart catheterization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain natriuretic peptide (BNP) &ndash; A plasma BNP level below 100",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      favors ARDS, but higher levels neither confirm heart failure nor exclude ARDS [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. This derives from an observational study of patients with ARDS (n = 33) or cardiogenic pulmonary edema (n = 21) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/27\">",
"       27",
"      </a>",
"      ]. The study found that a plasma BNP level less than 100",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      identified ARDS with a sensitivity, specificity, positive predictive value, and negative predictive value of 27, 95, 90, and 44 percent, respectively.",
"     </li>",
"     <li>",
"      Echocardiography &ndash; Many clinicians use transthoracic echocardiography as the first-line diagnostic test if cardiogenic pulmonary edema cannot be excluded by clinical evaluation and measurement of the BNP level. While severe aortic or mitral valve dysfunction, severe diastolic dysfunction, or a severely reduced left ventricular ejection fraction favors cardiogenic pulmonary edema, the latter is insufficient to confirm primary cardiogenic pulmonary edema because some precipitants of ARDS (eg, septic shock) can cause an acute, severe cardiomyopathy that develops concomitantly with ARDS [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. In addition, cardiogenic pulmonary edema cannot be excluded on the basis of an echocardiogram, since diastolic dysfunction and volume overload may exist even if the left heart function appears normal.",
"     </li>",
"     <li>",
"      Right heart catheterization &ndash; There is ample evidence that there is generally no value to routine right heart catheterization for either the diagnosis or management of ARDS [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. However, pulmonary artery catheterization may be considered if primary cardiogenic pulmonary edema cannot be excluded on the basis of the clinical evaluation, plasma BNP measurement, and echocardiogram. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link&amp;anchor=H11#H11\">",
"       \"Evaluation of acute decompensated heart failure\", section on 'Swan-Ganz catheter'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Excluding other causes of hypoxemic respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially treatable causes of ARDS and alternative forms of acute hypoxemic respiratory failure with bilateral infiltrates should be considered once cardiogenic pulmonary edema has been excluded. If such conditions cannot be identified on the basis of the clinical context and accompanying symptoms and signs, additional diagnostic testing should be performed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Noninvasive respiratory sampling &ndash; The lower respiratory tract can be sampled via tracheobronchial aspiration or mini-bronchoalveolar lavage (mini-BAL). Tracheobronchial aspiration is performed by advancing a catheter through the endotracheal tube until resistance is met and then applying suction, while mini-BAL is performed by advancing a catheter through the endotracheal tube until resistance is met, infusing sterile saline through the catheter, and then aspirating. Regardless of the technique, the specimen that is obtained may be evaluated via microscopic analysis (eg, Gram stain, cytology) and microbiologic culture; these studies may identify pneumonia or rapidly progressive cancer as the correct diagnosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flexible bronchoscopy &ndash; Flexible bronchoscopy can obtain lower respiratory samples for microscopic analysis and microbiologic culture if the noninvasive techniques are unsuccessful. It can also identify abnormalities that may not be detected with noninvasive sampling. Therefore, flexible bronchoscopy is a reasonable next step whenever noninvasive sampling is nondiagnostic.",
"      <br/>",
"      <br/>",
"      Consider the following examples of findings that suggest a specific etiology for acute hypoxemic respiratory failure. Frothy bloody secretions throughout the airways, increasing red blood cells in serial bronchoalveolar lavage (BAL) specimens, and hemosiderin-laden macrophages in the BAL fluid suggest diffuse alveolar hemorrhage. A large number of eosinophils in the BAL fluid suggest idiopathic acute eosinophilic pneumonia. And, recovery of lipid-laden macrophages or recognizable food particles suggest aspiration pneumonitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lung biopsy &ndash; Surgical lung biopsy may be considered when alternative causes of acute hypoxemic respiratory failure cannot be excluded on the basis of the clinical context, symptoms, signs, and bronchoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. The safety of lung biopsy in selected patients with hypoxemic respiratory failure was demonstrated by a retrospective study of 57 patients with ARDS who underwent open lung biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/33\">",
"       33",
"      </a>",
"      ]. The patients had a mean ratio of arterial oxygen tension to fraction of inspired oxygen",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"       )",
"      </span>",
"      of 145 mmHg and the rate of major complications was 7 percent, with no deaths attributed to the biopsy. Although the complication rate was 39 percent, most were tolerable (eg, persistent air leaks). The results of the biopsy resulted in the addition of specific therapy in 60 percent of patients and the withdrawal of unnecessary therapy in 37 percent.",
"      <br/>",
"      <br/>",
"      Generally speaking, we believe that lung biopsy should be reserved for carefully selected patients whose acute hypoxemic respiratory failure remains of uncertain etiology after nondiagnostic flexible bronchoscopy if one or more of the diagnostic possibilities under consideration might warrant targeted therapy or would substantially change the prognosis. Examples include cryptogenic organizing pneumonia, an acute fungal lung infection, an acute exacerbation of a chronic interstitial lung disease, vasculitis, or disseminated cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10171195\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARDS can be diagnosed once cardiogenic pulmonary edema and alternative causes of acute hypoxemic respiratory failure and bilateral infiltrates have been excluded. The Berlin Definition of ARDS requires that all of the following criteria be present to diagnose ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/2,35\">",
"     2,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory symptoms must have begun within one week of a known clinical insult, or the patient must have new or worsening symptoms during the past week.",
"     </li>",
"     <li>",
"      Bilateral opacities consistent with pulmonary edema must be present on a chest radiograph or computed tomographic (CT) scan. These opacities must not be fully explained by pleural effusions, lobar collapse, lung collapse, or pulmonary nodules.",
"     </li>",
"     <li>",
"      The patient&rsquo;s respiratory failure must not be fully explained by cardiac failure or fluid overload. An objective assessment (eg, echocardiography) to exclude hydrostatic pulmonary edema is required if no risk factors for ARDS are present.",
"     </li>",
"     <li>",
"      A moderate to severe impairment of oxygenation must be present, as defined by the ratio of arterial oxygen tension to fraction of inspired oxygen",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"       ).",
"      </span>",
"      The severity of the hypoxemia defines the severity of the ARDS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mild ARDS &ndash; The",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      is &gt;200 mmHg, but &le;300 mmHg, on ventilator settings that include positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) &ge;5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O.",
"     </li>",
"     <li>",
"      Moderate ARDS &ndash; The",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      is &gt;100 mmHg, but &le;200 mmHg, on ventilator settings that include PEEP &ge;5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O.",
"     </li>",
"     <li>",
"      Severe ARDS &ndash; The",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      is &le;100 mmHg on ventilators setting that include PEEP &ge;5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To determine the",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    ratio, the PaO",
"    <sub>",
"     2",
"    </sub>",
"    is measured in mmHg and the FiO",
"    <sub>",
"     2",
"    </sub>",
"    is expressed as a decimal between 0.21 and 1. As an example, if a patient has a PaO",
"    <sub>",
"     2",
"    </sub>",
"    of 60 mmHg while receiving 80 percent oxygen, then the",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    is 60",
"    <span class=\"nowrap\">",
"     mmHg/0.8",
"    </span>",
"    = 75 mmHg. Determining the",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    requires arterial blood gas (ABG) analysis, which can be difficult to obtain from some patients. For such patients, the ratio of oxyhemoglobin saturation measured by pulse oximetry (SpO",
"    <sub>",
"     2",
"    </sub>",
"    ) to FiO",
"    <sub>",
"     2",
"    </sub>",
"    is a reasonable substitute, according to a retrospective study of ABG measurements performed in adults receiving mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/36\">",
"     36",
"    </a>",
"    ]. The study found that a",
"    <span class=\"nowrap\">",
"     SpO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    of 315 predicted a",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    of 300 (the threshold for ARDS) with a sensitivity of 91 percent and a specificity of 56 percent.",
"   </p>",
"   <p>",
"    The Berlin Definition of ARDS (published in 2012) replaces the American-European Consensus Conference&rsquo;s definition of ARDS (published in 1994) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/16,37\">",
"     16,37",
"    </a>",
"    ]. The major changes to the Berlin Definition are that the term &ldquo;acute lung injury&rdquo; has been eliminated, the pulmonary capillary wedge pressure (ie, pulmonary artery occlusion pressure) criterion has been removed, and minimal ventilator settings have been added.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10171357\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of alternative conditions may present as acute hypoxemic respiratory failure with bilateral alveolar infiltrates and, therefore, should be considered whenever ARDS is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiogenic pulmonary edema is usually due to left ventricular systolic or diastolic dysfunction, but may also be due to fluid overload, severe hypertension, renal artery stenosis, or severe renal disease. Its presentation is nearly identical to ARDS, except there may be evidence of cardiac dysfunction (eg, an S3 or S4 gallop, new or changed murmur), elevated right-sided filling pressures (eg, elevated jugular venous pressure), or related radiographic abnormalities (eg, pulmonary venous congestion, Kerley B lines, cardiomegaly, and pleural effusions). Distinguishing cardiogenic pulmonary edema from ARDS can be aided by measurement of a brain natriuretic peptide (BNP) level, echocardiography, and, less often, right heart catheterization. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Excluding cardiogenic pulmonary edema'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"       \"Evaluation of acute decompensated heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An acute exacerbation of idiopathic pulmonary fibrosis or other chronic interstitial lung diseases can closely resemble ARDS in both clinical presentation and chest radiographic abnormalities. Like ARDS, the pathological findings are dominated by diffuse alveolar damage, but the prognosis is substantially worse. This diagnostic possibility is easily overlooked in patients whose underlying interstitial lung disease is unknown or mild or moderate in severity. The diagnosis is suggested by careful review of previous chest radiographic images, by discovery of subpleural reticulocytic changes intermixed with alveolar opacities on a chest CT scan obtained shortly after onset of ARDS, or by surgical lung biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=see_link&amp;anchor=H25#H25\">",
"       \"Treatment of idiopathic pulmonary fibrosis\", section on 'Acute exacerbations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diffuse alveolar hemorrhage may be associated with a large, otherwise unexplained drop in the hemoglobin concentration and hematocrit. While hemoptysis may be minimal or absent, bronchoscopy often reveals frothy bloody secretions throughout the airways and invariably detects an increasing amount of red blood cells in serial bronchoalveolar lavage specimens. The recovery of hemosiderin-laden macrophages from bronchoalveolar lavage fluid is strongly suggestive of diffuse alveolar hemorrhage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"       \"The diffuse alveolar hemorrhage syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Idiopathic acute eosinophilic pneumonia (IAEP) occurs in previously healthy individuals and is characterized by cough, fever, dyspnea, and sometimes chest pain. Bronchoalveolar lavage specimens always contain a large number of eosinophils, typically 35 to 55 percent of all recovered cells [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. Peripheral eosinophil may or may not be present [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10505/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=see_link\">",
"       \"Idiopathic acute eosinophilic pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cryptogenic organizing pneumonia (COP) often mimics community-acquired pneumonia with an onset that is heralded by a flu-like illness with fever, malaise, fatigue, and cough. The most common features at presentation are a persistent nonproductive cough, dyspnea with exertion, and weight loss. Bronchoalveolar lavage usually contains a smaller proportion of macrophages and higher proportions of lymphocytes, neutrophils, and eosinophils than healthy patients. This \"mixed pattern\" of increased cellularity is thought to be characteristic of COP. The diagnosis is made by ruling out infectious causes of pneumonia and documenting typical pathologic changes in tissue obtained by open lung biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"       \"Cryptogenic organizing pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute interstitial pneumonia (Hamman-Rich syndrome) is a rare and fulminant form of diffuse lung injury that has a presentation similar to ARDS. Many people consider acute interstitial pneumonia a subset of idiopathic ARDS since its clinical manifestations are similar and both demonstrate diffuse alveolar damage on histopathology. The distinguishing characteristic is that ARDS is often associated with a known risk factor, whereas acute interstitial pneumonia is not. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=see_link\">",
"       \"Acute interstitial pneumonia (Hamman-Rich syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cancer can disseminate through the lungs so rapidly that the ensuing respiratory failure may be mistaken for ARDS. This is most often due to lymphoma or acute leukemia, but lymphangitic spread of solid tumors occasionally behaves this way. Cytological preparation of bronchoscopic specimens (eg, brushings, lavage) may reveal malignant cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=see_link\">",
"       \"Patient information: Adult respiratory distress syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of acute respiratory distress syndrome (ARDS) requires that all of the following criteria be present (see",
"      <a class=\"local\" href=\"#H10171195\">",
"       'Diagnostic criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Respiratory symptoms must have begun within one week of a known clinical insult, or the patient must have new or worsening symptoms during the past week.",
"     </li>",
"     <li>",
"      Bilateral opacities consistent with pulmonary edema must be present on a chest radiograph or computed tomographic (CT) scan. These opacities must not be fully explained by pleural effusions, lobar collapse, lung collapse, or pulmonary nodules.",
"     </li>",
"     <li>",
"      The patient&rsquo;s respiratory failure must not be fully explained by cardiac failure or fluid overload. An objective assessment (eg, echocardiography) to exclude hydrostatic pulmonary edema is required if no risk factors for ARDS are present.",
"     </li>",
"     <li>",
"      Hypoxemia must be present on minimal ventilator settings, as defined by the ratio of arterial oxygen tension to fraction of inspired oxygen",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"       ).",
"      </span>",
"      The severity of the hypoxemia defines the severity of the ARDS. Mild ARDS exists when the",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      is &gt;200 mmHg, but &le;300 mmHg, on invasive or non-invasive ventilator settings that include a positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) &ge;5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O. Moderate ARDS exists when the",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      is &gt;100 mmHg, but &le;200 mmHg, on ventilator settings that include a PEEP &ge;5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O. And, severe ARDS exists when the",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      is &le;100 mmHg on ventilator settings that include a PEEP &ge;5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ARDS typically present with respiratory distress characterized by dyspnea, hypoxemia, bilateral alveolar infiltrates, and diffuse crackles. These findings usually begin within 48 to 72 hours of the inciting event and then rapidly worsen. High concentrations of supplemental oxygen are generally needed. (See",
"      <a class=\"local\" href=\"#H10171119\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who survive the initial course usually begin to exhibit better oxygenation and decreasing alveolar infiltrates over the next several days. The amount of ventilatory support required may decrease and weaning may begin. Some patients, however, have persistent interstitial infiltrates and remain ventilator-dependent. Development of pulmonary fibrosis may follow and the clinical course may become dominated by persistent ventilator dependence and various complications (eg, pulmonary barotrauma, nosocomial pneumonia). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical course'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ARDS is a diagnosis of exclusion. Therefore, the diagnostic evaluation is aimed at excluding other causes of acute hypoxemic respiratory failure with bilateral alveolar infiltrates.",
"      <strong>",
"      </strong>",
"      Cardiogenic pulmonary edema is the primary alternative that needs to be excluded. This may require diagnostic testing (eg, brain natriuretic peptide [BNP] levels, echocardiography,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      right heart catheterization). Alternative causes of acute hypoxemic respiratory failure with bilateral infiltrates should be considered once cardiogenic pulmonary edema has been excluded and, if such diseases cannot be excluded on the basis of the clinical context and accompanying symptoms and signs, additional diagnostic testing should be performed. This may include noninvasive respiratory sampling, flexible bronchoscopy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lung biopsy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of alternative conditions may present as acute hypoxemic respiratory failure with bilateral alveolar infiltrates and, therefore, should be considered whenever ARDS is suspected. They include cardiogenic pulmonary edema, diffuse alveolar hemorrhage, idiopathic acute exacerbation of pre-existing interstitial lung disease, acute eosinophilic pneumonia, cryptogenic organizing pneumonia, acute interstitial pneumonia, and rapidly disseminating cancer. (See",
"      <a class=\"local\" href=\"#H10171357\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/1\">",
"      Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967; 2:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/2\">",
"      The ARDS Definition Task Force. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA 2012; May 21, 2012:Epub ahead of print.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/3\">",
"      Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/4\">",
"      Goodman LR. Congestive heart failure and adult respiratory distress syndrome. New insights using computed tomography. Radiol Clin North Am 1996; 34:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/5\">",
"      Gattinoni L, Presenti A, Torresin A, et al. Adult respiratory distress syndrome profiles by computed tomography. J Thorac Imaging 1986; 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/6\">",
"      Pelosi P, Crotti S, Brazzi L, Gattinoni L. Computed tomography in adult respiratory distress syndrome: what has it taught us? Eur Respir J 1996; 9:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/7\">",
"      Rubenfeld GD, Caldwell E, Granton J, et al. Interobserver variability in applying a radiographic definition for ARDS. Chest 1999; 116:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/8\">",
"      Herridge MS, Tansey CM, Matt&eacute; A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 2011; 364:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/9\">",
"      Mikkelsen ME, Christie JD, Lanken PN, et al. The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury. Am J Respir Crit Care Med 2012; 185:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/10\">",
"      Gammon RB, Shin MS, Buchalter SE. Pulmonary barotrauma in mechanical ventilation. Patterns and risk factors. Chest 1992; 102:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/11\">",
"      Gammon RB, Shin MS, Groves RH Jr, et al. Clinical risk factors for pulmonary barotrauma: a multivariate analysis. Am J Respir Crit Care Med 1995; 152:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/12\">",
"      Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/13\">",
"      Boussarsar M, Thierry G, Jaber S, et al. Relationship between ventilatory settings and barotrauma in the acute respiratory distress syndrome. Intensive Care Med 2002; 28:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/14\">",
"      Schnapp LM, Chin DP, Szaflarski N, Matthay MA. Frequency and importance of barotrauma in 100 patients with acute lung injury. Crit Care Med 1995; 23:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/15\">",
"      Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med 2001; 29:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/16\">",
"      Artigas A, Bernard GR, Carlet J, et al. The American-European Consensus Conference on ARDS, part 2: Ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/17\">",
"      Bercker S, Weber-Carstens S, Deja M, et al. Critical illness polyneuropathy and myopathy in patients with acute respiratory distress syndrome. Crit Care Med 2005; 33:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/18\">",
"      van den Boogaard M, Schoonhoven L, Evers AW, et al. Delirium in critically ill patients: impact on long-term health-related quality of life and cognitive functioning. Crit Care Med 2012; 40:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/19\">",
"      Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/20\">",
"      Seidenfeld JJ, Pohl DF, Bell RC, et al. Incidence, site, and outcome of infections in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1986; 134:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/21\">",
"      Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995; 108:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/22\">",
"      Fagon JY, Chastre J, Vuagnat A, et al. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 1996; 275:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/23\">",
"      Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/24\">",
"      Sutherland KR, Steinberg KP, Maunder RJ, et al. Pulmonary infection during the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/25\">",
"      Andrews CP, Coalson JJ, Smith JD, Johanson WG Jr. Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury. Chest 1981; 80:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/26\">",
"      Chastre J, Trouillet JL, Vuagnat A, et al. Nosocomial pneumonia in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/27\">",
"      Levitt JE, Vinayak AG, Gehlbach BK, et al. Diagnostic utility of B-type natriuretic peptide in critically ill patients with pulmonary edema: a prospective cohort study. Crit Care 2008; 12:R3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/28\">",
"      Rudiger A, Gasser S, Fischler M, et al. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006; 34:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/29\">",
"      Bouhemad B, Nicolas-Robin A, Arbelot C, et al. Acute left ventricular dilatation and shock-induced myocardial dysfunction. Crit Care Med 2009; 37:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/30\">",
"      Landesberg G, Gilon D, Meroz Y, et al. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J 2012; 33:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/31\">",
"      National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/32\">",
"      Richard C, Warszawski J, Anguel N, et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2003; 290:2713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/33\">",
"      Patel SR, Karmpaliotis D, Ayas NT, et al. The role of open-lung biopsy in ARDS. Chest 2004; 125:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/34\">",
"      Papazian L, Thomas P, Bregeon F, et al. Open-lung biopsy in patients with acute respiratory distress syndrome. Anesthesiology 1998; 88:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/35\">",
"      Ferguson ND, Fan E, Camporota L, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med 2012; 38:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/36\">",
"      Rice TW, Wheeler AP, Bernard GR, et al. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest 2007; 132:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/37\">",
"      Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/38\">",
"      Schwarz MI, Albert RK. \"Imitators\" of the ARDS: implications for diagnosis and treatment. Chest 2004; 125:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/39\">",
"      Pope-Harman AL, Davis WB, Allen ED, et al. Acute eosinophilic pneumonia. A summary of 15 cases and review of the literature. Medicine (Baltimore) 1996; 75:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/40\">",
"      Buchheit J, Eid N, Rodgers G Jr, et al. Acute eosinophilic pneumonia with respiratory failure: a new syndrome? Am Rev Respir Dis 1992; 145:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10505/abstract/41\">",
"      Philit F, Etienne-Mastro&iuml;anni B, Parrot A, et al. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002; 166:1235.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1637 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10505=[""].join("\n");
var outline_f10_16_10505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10171119\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Barotrauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Delirium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Nosocomial infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Excluding cardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Excluding other causes of hypoxemic respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10171195\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10171357\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1637\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1637|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/38/13920\" title=\"diagnostic image 1\">",
"      ARDS PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/43/39601\" title=\"diagnostic image 2\">",
"      ARDS CT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?30/51/31539?source=related_link\" title=\"calculator 1\">",
"      Calculator: A-a gradient (alveolar-arterial gradient; AaG)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=related_link\">",
"      Acute interstitial pneumonia (Hamman-Rich syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=related_link\">",
"      Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4871?source=related_link\">",
"      Acute respiratory distress syndrome: Prognosis and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=related_link\">",
"      Idiopathic acute eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14423?source=related_link\">",
"      Methods of weaning from mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=related_link\">",
"      Novel therapies for the acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=related_link\">",
"      Patient information: Adult respiratory distress syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=related_link\">",
"      Pulmonary barotrauma during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=related_link\">",
"      Treatment of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21112?source=related_link\">",
"      Weaning from mechanical ventilation: Readiness testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_16_10506="Noninvasive diagnosis of arterial disease";
var content_f10_16_10506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Noninvasive diagnosis of arterial disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/16/10506/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/16/10506/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/16/10506/contributors\">",
"     Erica Mitchell, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/16/10506/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/16/10506/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/16/10506/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/16/10506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/16/10506/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/16/10506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H58544613\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the patient with arterial disease begins with a thorough history and physical examination and uses noninvasive vascular studies as an adjunct to confirm a clinical diagnosis and further define the level and extent of vascular pathology. Vascular testing may be indicated for patients with suspected arterial disease based upon symptoms (eg, intermittent claudication), physical examination findings (eg, signs of tissue ischemia), or in patients with risk factors for atherosclerosis (eg, smoking, diabetes mellitus) or other arterial pathology (eg, trauma, peripheral embolism) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of noninvasive examinations are available to assess the presence and severity of arterial disease. Physiologic tests include segmental limb pressures and the calculation of pressure index values (eg, ankle-brachial index, wrist-brachial index), exercise testing, segmental volume plethysmography, transcutaneous oxygen measurements and photoplethysmography. &nbsp;",
"   </p>",
"   <p>",
"    Ultrasound is the mainstay for vascular imaging with each mode (eg, B-mode, duplex) providing specific information that is useful depending upon the vascular disorder. Other studies frequently used to image the vasculature include computed tomography (CT) and magnetic resonance (MR) imaging. CT and MR imaging are important alternative methods for vascular assessment; however, the cost and the time necessary for these studies limit their use for routine testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/2\">",
"     2",
"    </a>",
"    ]. Contrast arteriography remains the gold standard for vascular imaging and at times can be a primary imaging modality, particularly if intervention is being considered. The role of these imaging in specific vascular disorders are discussed in detail separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58544620\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for noninvasive vascular testing to supplement the history and physical examination depends upon the clinical scenario and urgency of the patient&rsquo;s condition. An exhaustive battery of tests is not required in all patients to evaluate their vascular status. In general, only tests that confirm the presence of arterial disease or provide information that will alter the course of treatment should be performed.",
"   </p>",
"   <p>",
"    Patients can be asymptomatic, have classic symptoms of peripheral artery disease (PAD) such as claudication, or more atypical symptoms. Symptoms vary depending upon the vascular bed affected, the nature and severity of the disease and the presence and effectiveness of collateral circulation. The clinical presentations of various vascular disorders are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=see_link\">",
"     \"Overview of thoracic outlet syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noninvasive vascular testing may be performed to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screen patients who have risk factors for PAD. Patients with asymptomatic lower extremity PAD have an increased risk of myocardial infarction, stroke, and cardiovascular mortality and benefit from identification to provide risk factor modification [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/3-8\">",
"       3-8",
"      </a>",
"      ]. Similarly, asymptomatic patients with risk factors for aneurysm or cerebrovascular disease may be screened to identify these conditions and stratify management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24200?source=see_link\">",
"       \"Screening for lower extremity peripheral artery disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24488?source=see_link\">",
"       \"Screening for abdominal aortic aneurysm\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34361?source=see_link\">",
"       \"Screening for asymptomatic carotid artery stenosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Confirm a diagnosis of arterial disease in patients with symptoms or signs consistent with an arterial pathology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"       \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12245?source=see_link\">",
"       \"Overview of upper extremity peripheral artery disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3065?source=see_link\">",
"       \"Popliteal artery aneurysm\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33206?source=see_link\">",
"       \"Chronic mesenteric ischemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link\">",
"       \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Identify a vascular injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12186?source=see_link\">",
"       \"Severe extremity injury in the adult patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/16/266?source=see_link\">",
"       \"Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluate patients prior to or during planned vascular procedures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37210?source=see_link\">",
"       \"Creating an arteriovenous fistula for hemodialysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"       \"Treatment of chronic lower extremity critical limb ischemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Provide surveillance after vascular intervention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"       \"Treatment of chronic lower extremity critical limb ischemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38921?source=see_link\">",
"       \"Percutaneous interventional procedures in the patient with lower extremity claudication\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58549369\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main purpose of physiologic testing is to verify a vascular origin for a patient&rsquo;s specific complaint. Other goals, depending upon the clinical scenario, are to localize the level of obstructive lesions and assess the adequacy of tissue perfusion and wound healing potential. These objectives are met by obtaining one or more tests including segmental limb pressures, calculation of index values (ankle-brachial index, wrist-brachial index, toe-brachial index), pulse volume recordings, exercise testing, digit plethysmography and transcutaneous oxygen measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58544655\">",
"    <span class=\"h2\">",
"     Ankle-brachial index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calculation of the ankle-brachial index (ABI) is a relatively simple and inexpensive method to confirm the clinical suspicion of lower extremity arterial occlusive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. The resting systolic blood pressure at the ankle is compared with the systolic brachial pressure and the ratio of the two pressures defines the ankle-brachial (or ankle-arm) index. This index provides a measure of the severity of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patients must rest for 15 to 30 minutes prior to measuring the ankle pressure. To obtain the ABI, place a blood pressure cuff just above the ankle. While listening to either the dorsalis pedis or posterior tibial artery signal with a continuous wave Doppler (",
"    <a class=\"graphic graphic_picture graphicRef76440 \" href=\"UTD.htm?34/24/35203\">",
"     picture 1",
"    </a>",
"    ) , insufflate the cuff to a pressure above which the audible Doppler signal disappears. Slowly release the pressure in the cuff just until the pedal signal returns and record this systolic pressure. Repeat the measurement in the same manner for the other pedal vessel in the ipsilateral extremity and repeat the process in the contralateral lower extremity. Measure the systolic brachial artery pressure bilaterally in a similar fashion with the blood pressure cuff placed around the upper arm and using the continuous wave Doppler. The ABI for each lower extremity is calculated by dividing the higher ankle pressure (dorsalis pedis or posterior tibial artery) in each lower extremity by the higher of the two brachial artery systolic pressures.",
"   </p>",
"   <p>",
"    Calculation of the ankle-brachial index (ABI) at the bedside is usually performed with a continuous-wave Doppler probe (",
"    <a class=\"graphic graphic_picture graphicRef76440 \" href=\"UTD.htm?34/24/35203\">",
"     picture 1",
"    </a>",
"    ). The disadvantage of using continuous wave Doppler is a lack of sensitivity at extremely low pressures where it may be difficult to distinguish arterial from venous flow. A venous signal can be confused with an arterial signal (especially if pulsatile venous flow is present, as can occur with heart failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Under these conditions, duplex ultrasound can be used to distinguish between arteries and veins by identifying the direction of flow. (See",
"    <a class=\"local\" href=\"#H58549051\">",
"     'Continuous wave Doppler'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H58548990\">",
"     'Duplex imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The ABI is generally, but not absolutely, correlated with clinical measures of lower extremity function such as walking distance, speed of walking, balance, and overall physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. Further evaluation is dependent upon the ABI value (",
"    <a class=\"graphic graphic_algorithm graphicRef85752 graphicRef50445 \" href=\"UTD.htm?37/0/37903\">",
"     algorithm 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal ABI is &ge;0.9 to as high as 1.3. Normally, the pressure is higher in the ankle than in the arm. A normal test generally excludes arterial occlusive disease. Mild disease and arterial entrapment syndromes can produce false negative tests. If ABIs are normal at rest but symptoms strongly suggest claudication, exercise testing should be performed [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H146789783\">",
"       'Exercise testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      An ABI &gt;1.3 suggests the presence of calcified vessels and the need for additional vascular studies, such as pulse volume recordings, measurement of the toe pressures and toe-brachial index, or arterial duplex studies. (See",
"      <a class=\"local\" href=\"#H58544669\">",
"       'High ABI'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H58549539\">",
"       'Toe-brachial index'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H58548990\">",
"       'Duplex imaging'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      An ABI &le;0.9 is diagnostic of occlusive arterial disease in patients with symptoms of claudication or other signs of ischemia and has 95 percent sensitivity (and 100 percent specificity) for detecting arteriogram-positive occlusive lesions associated with &ge;50 percent stenosis in one or more major vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An ABI of 0.4 to 0.9 suggests a degree of arterial obstruction often associated with claudication [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An ABI below 0.4 represents multilevel disease (any combination of iliac, femoral or tibial vessel disease) and may be associated with non-healing ulcerations, ischemic rest pain or pedal gangrene. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=see_link\">",
"       \"Clinical manifestations and evaluation of chronic critical limb ischemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A low ABI is associated with a higher risk of coronary heart disease, stroke, transient ischemic attack, progressive renal insufficiency, and all-cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/20-25\">",
"     20-25",
"    </a>",
"    ]. Screening for asymptomatic PAD is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24200?source=see_link\">",
"     \"Screening for lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study among nearly 1500 women, 5.5 percent had an ABI of &lt;0.9,",
"      <span class=\"nowrap\">",
"       67/82",
"      </span>",
"      of whom had no symptoms consistent with peripheral artery disease. Compared with the cohort with an index &gt;0.9, this group had markedly increased relative risks of 3.1 and 3.7 for death and coronary heart disease, respectively, at four years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report from the Framingham study of 251 men and 423 women (mean age 80 years), 21 percent had an ABI &lt;0.9 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/23\">",
"       23",
"      </a>",
"      ]. Those with a low ABI had, at four years, a significantly increased risk of transient ischemic attack or stroke (13 versus 5 percent).",
"     </li>",
"     <li>",
"      In a study of 262 patients, the ankle brachial index was measured in patients with type 2 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/25\">",
"       25",
"      </a>",
"      ]. During the 10-year follow-up period, all nonfatal cardiovascular events and mortality were recorded. The mortality rates for patients with normal and abnormal ABI were 17 and 53 percent, respectively. The incidence of cardiovascular events (coronary, cerebrovascular) was 27 percent (95% CI, 20.7-37.3) for the patients with a normal baseline ABI, and 82 percent (95% CI 50.9-131.8) when the baseline ABI was abnormal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58544669\">",
"    <span class=\"h3\">",
"     High ABI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential source of error with the ABI is that calcified vessels may not compress normally, thereby resulting in falsely elevated pressure measurements. An ABI above 1.3 is suspicious for calcified vessels and may also be associated with leg pain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/18\">",
"     18",
"    </a>",
"    ]. The National Health and Nutrition Survey (NHANES) estimated that 1.4 percent of adults age &gt;40 years in the United States have an ABI &gt;1.4; this group accounts for approximately 20 percent of all adults with PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with low ABI, abnormally high ABI (&gt;1.3) is also associated with higher cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/22,27\">",
"     22,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Multi-Ethnic Study of Atherosclerosis (MESA) study evaluated 4972 patients without clinical cardiovascular disease and found a greater left ventricular mass index in patients with high ABI (&gt;1.4) compared with normal ABI (90 versus 72",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/27\">",
"       27",
"      </a>",
"      ]. Increases in left ventricular mass are predominantly attributable to an increase in afterload. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=see_link\">",
"       \"Definition and pathogenesis of left ventricular hypertrophy in hypertension\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      The Strong Heart Study followed 4393 Native American patients for a mean of eight years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/22\">",
"       22",
"      </a>",
"      ]. High ABI (&gt;1.4) was present in 9.2 percent of patients and low ABI (&le;0.9) was found in 4.9 percent of patients. Adjusted hazard ratios for all-cause mortality and cardiovascular mortality rates were 1.8 and 2.0, respectively, for high ABI and 1.7 and 2.5, respectively, for low ABI relative to normal ABI (0.9&lt;ABI&le;1.4). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with arterial calcification, such as patients with diabetes, more reliable information is often obtained using toe pressures and calculation of the toe-brachial index, and pulse volume recordings. (See",
"    <a class=\"local\" href=\"#H58549539\">",
"     'Toe-brachial index'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H58544704\">",
"     'Pulse volume recordings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58549402\">",
"    <span class=\"h2\">",
"     Wrist-brachial index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wrist-brachial index (WBI) is used to identify the level and extent of upper extremity arterial occlusive disease. Upper extremity disease is far less common than lower extremity disease and abnormalities in WBI have not been correlated with adverse cardiovascular risk as seen with ABI. Thus, WBIs are typically measured only when the patient has clinical signs or symptoms consistent with upper extremity arterial stenosis or occlusion. The WBI is obtained in a manner analogous to the ABI. (See",
"    <a class=\"local\" href=\"#H58544655\">",
"     'Ankle-brachial index'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Pressure measurements are obtained for the radial and ulnar arteries at the wrist and brachial arteries in each extremity. The WBI for each upper extremity is calculated by dividing the highest wrist pressure (radial artery or ulnar artery) by the higher of the two brachial artery pressures. The normal value for the WBI is 1.0.",
"   </p>",
"   <p>",
"    Incompressibility can also occur in the upper extremity. The radial or ulnar arteries may have a supranormal wrist-brachial index. This finding may indicate the presence of medial calcification in the patient with diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58549539\">",
"    <span class=\"h2\">",
"     Toe-brachial index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toe-brachial index (TBI) is a more reliable indicator of limb perfusion in patients with diabetes because the small vessels of the toes are frequently spared from medial calcification.",
"   </p>",
"   <p>",
"    The TBI is obtained by placing a pneumatic cuff on one of the toes. The great toe is usually chosen but in the face of amputation the second or other toe is used. A photo-electrode is placed on the end of the toe to obtain a photoplethysmographic (PPG) arterial waveform using infrared light (",
"    <a class=\"graphic graphic_figure graphicRef71292 \" href=\"UTD.htm?9/13/9429\">",
"     figure 1",
"    </a>",
"    ). The infrared light is transmitted into the superficial layers of the skin and the reflected portion is received by a photosensor within the photo-electrode. The signal is proportional to the quantity of red blood cells in the cutaneous circulation.",
"   </p>",
"   <p>",
"    Analogous to the ankle and wrist pressure measurements, the toe cuff is inflated until the PPG waveform flattens and then the cuff is slowly deflated. The systolic pressure is recorded at the point in which the baseline waveform is re-established. The ratio of the recorded toe systolic pressure to the higher of the two brachial pressures gives the TBI.",
"   </p>",
"   <p>",
"    A pressure gradient of 20 to 30 mmHg normally exists between the ankle and the toe, and thus, a normal toe-brachial index is 0.7 to 0.8. An absolute toe pressure &gt;30 mmHg is favorable for wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/28\">",
"     28",
"    </a>",
"    ], although toe pressures &gt;45 to 55 mmHg may be required for healing in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Toe pressures are useful to define perfusion at the level of the foot, especially in patients with incompressible vessels, but they provide no indication of the site of occlusive disease. In addition to measuring toe systolic pressures, the toe Doppler arterial waveforms should also be evaluated. (See",
"    <a class=\"local\" href=\"#H58544704\">",
"     'Pulse volume recordings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58544690\">",
"    <span class=\"h2\">",
"     Segmental pressures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once arterial occlusive disease has been verified using the ankle-brachial index (ABI) measurements (resting or post-exercise) (see",
"    <a class=\"local\" href=\"#H146789783\">",
"     'Exercise testing'",
"    </a>",
"    below), the level and extent of disease can be determined using segmental limb pressures which are performed using specialized equipment in the vascular laboratory. Blood pressures are obtained at successive levels of the extremity, localizing the level of disease fairly accurately. Segmental pressures can be obtained for the upper or lower extremity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146789823\">",
"    <span class=\"h3\">",
"     Lower extremity segmental pressures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is placed in a supine position and rested for 15 minutes. Three or four standard-sized blood pressure cuffs are placed at several positions on the extremity. A three-cuff technique uses above knee, below knee, and ankle cuffs. A four-cuff technique (",
"    <a class=\"graphic graphic_picture graphicRef80197 \" href=\"UTD.htm?32/23/33137\">",
"     picture 2",
"    </a>",
"    ) uses two narrower blood pressure cuffs rather than one large cuff on the thigh and permits the differentiation of aortoiliac and superficial femoral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pedal vessel (dorsalis pedis, posterior tibial) with the higher systolic pressure is used, and the pressure that occludes the pedal signal for each cuff level is measured by first inflating the cuff until the signal is no longer heard and then progressively deflating the cuff until the signal resumes. The pressure at each level is divided by the higher systolic arm pressure to obtain an index value for each level (",
"    <a class=\"graphic graphic_figure graphicRef58549 \" href=\"UTD.htm?42/1/43033\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A 20 mmHg or greater reduction in pressure is indicative of a flow-limiting lesion if the pressure difference is present either between segments along the same leg or when compared with the same level in the opposite leg (ie, right",
"    <span class=\"nowrap\">",
"     thigh/left",
"    </span>",
"    thigh, right",
"    <span class=\"nowrap\">",
"     calf/left",
"    </span>",
"    calf) (",
"    <a class=\"graphic graphic_figure graphicRef58549 \" href=\"UTD.htm?42/1/43033\">",
"     figure 2",
"    </a>",
"    ). Well-developed collateral vessels may diminish the observed pressure gradient and obscure a hemodynamically significant lesion. Successive significant (&gt;20 mmHg) decrements in the same extremity indicate multilevel disease.",
"   </p>",
"   <p>",
"    Pressure gradients may be increased in the hypertensive patient and decreased in patients with low cardiac output. When performing serial examinations over time, changes in index values &gt;0.15 from one study to the next are considered significant and suggest progression of disease.",
"   </p>",
"   <p>",
"    With a four cuff technique, the high-thigh pressure should be higher than the brachial pressure, though in the normal individual, these pressures would be nearly equal if measured by invasive means. The four-cuff technique introduces artifact because the high-thigh cuff is often not appropriately 120 percent the diameter of the thigh at the cuff site. A &gt;30 mmHg decrement between the highest systolic brachial pressure and high-thigh pressure is considered abnormal.",
"   </p>",
"   <p>",
"    A normal high-thigh pressure excludes occlusive disease proximal to the bifurcation of the common femoral artery. If the high-thigh systolic pressure is reduced compared with the brachial pressure, then the patient has a lesion at or proximal to the bifurcation of the common femoral artery. If the high-thigh pressure is normal but the low-thigh pressure is decreased, the lesion is in the superficial femoral artery. In one prospective study, the four-cuff technique correctly identified the level of the occlusive lesion in 78 percent of extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with claudication, the localization of the lesion may have been suspected from their history. The site of pain and site of arterial disease correlates with pressure reductions seen on segmental pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/3,33\">",
"     3,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Buttock, hip or thigh pain &ndash; Pressure gradient between the brachial artery and the upper thigh is consistent with arterial occlusive disease at or proximal to the bifurcation of the common femoral artery.",
"     </li>",
"     <li>",
"      Calf pain &ndash; Pressure gradient from the high to lower thigh indicates superficial femoral artery disease. Pressure gradient from the lower thigh to calf reflects popliteal disease.",
"     </li>",
"     <li>",
"      Low calf pain &ndash; Pressure gradient from the calf and ankle is indicative of infrapopliteal disease.",
"     </li>",
"     <li>",
"      Foot pain &ndash; Pressure gradient from the ankle and toe suggests digital artery occlusive disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with ABI measurements, segmental pressure measurements in the lower extremity may be artifactually increased or not interpretable in patients with non-compressible vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with diabetes who have medial sclerosis and patients with chronic kidney disease often have nonocclusive pressures with ABIs &gt;1.3, limiting the utility of segmental pressures in these populations. Pulse volume recordings which are independent of arterial compression are preferentially used instead. (See",
"    <a class=\"local\" href=\"#H58544704\">",
"     'Pulse volume recordings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146789830\">",
"    <span class=\"h3\">",
"     Upper extremity segmental pressures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Segmental pressures may also be performed in the upper extremity. Generally, three cuffs are used with above and below elbow cuffs and a wrist cuff (",
"    <a class=\"graphic graphic_figure graphicRef68027 \" href=\"UTD.htm?3/19/3386\">",
"     figure 3",
"    </a>",
"    ). Index values are calculated at each level. In the patient with possible upper extremity occlusive disease, a difference of &ge;10 mmHg between the left and right brachial systolic pressures suggests innominate, subclavian, axillary, or proximal brachial arterial occlusion. Differences of more than 10 to 20 mmHg between successive arm levels suggest intervening occlusive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58544704\">",
"    <span class=\"h2\">",
"     Pulse volume recordings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern vascular testing machines use air plethysmography to measure volume changes within the limb, in conjunction with segmental limb pressure measurement. The same pressure cuffs are used for each test (",
"    <a class=\"graphic graphic_picture graphicRef80197 \" href=\"UTD.htm?32/23/33137\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H58544690\">",
"     'Segmental pressures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cuffs are placed and inflated, one at a time, to a constant standard pressure. Volume changes in the limb segment beneath the cuff are reflected as changes in pressure within the cuff, which is detected by a pressure transducer and converted to an electrical signal to produce an analog pressure pulse contour known as a pulse volume recording (PVR).",
"   </p>",
"   <p>",
"    A normal PVR waveform is composed of a systolic upstroke with a sharp systolic peak followed by a downstroke that contains a prominent dicrotic notch (",
"    <a class=\"graphic graphic_picture graphicRef68273 \" href=\"UTD.htm?35/33/36381\">",
"     picture 3",
"    </a>",
"    ). Alterations in the pulse volume contour and amplitude indicate proximal arterial obstruction. The degree of these changes reflects disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Mild disease is characterized by loss of the dicrotic notch and an outward &ldquo;bowing&rdquo; of the downstroke of the waveform (",
"    <a class=\"graphic graphic_picture graphicRef68273 \" href=\"UTD.htm?35/33/36381\">",
"     picture 3",
"    </a>",
"    ). With severe disease, the amplitude of the waveform is blunted (",
"    <a class=\"graphic graphic_picture graphicRef68273 \" href=\"UTD.htm?35/33/36381\">",
"     picture 3",
"    </a>",
"    ). Pulse volume recordings are most useful in detecting disease in calcified vessels which tend to yield falsely elevated pressure measurements. (See",
"    <a class=\"local\" href=\"#H58544669\">",
"     'High ABI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Since the absolute amplitude of plethysmographic recordings is influenced by cardiac output and vasomotor tone, interpretation of these measurements should be limited to the comparison of one extremity to the other in the same patient and not between patients. The dicrotic notch may be absent in normal arteries in the presence of low resistance, such as after exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86998053\">",
"    <span class=\"h3\">",
"     Digit waveforms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with distal extremity small artery occlusive disease (eg, Buerger&rsquo;s disease, Raynaud&rsquo;s, end-stage renal disease, diabetes mellitus) often have normal ankle-brachial index and wrist-brachial index values. Arterial occlusion distal to the ankle or wrist can be detected using digit plethysmography, which is performed by placing small pneumatic cuffs on each of the digits of the hands or feet depending upon the disease being investigated. In a manner analogous to pulse volume recordings described above, volume changes in the digit segment beneath the cuff are detected and converted to produce an analog digit waveform. (See",
"    <a class=\"local\" href=\"#H58544704\">",
"     'Pulse volume recordings'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146789783\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Segmental blood pressure testing, toe-brachial index measurements and PVR waveforms can be obtained before and after exercise to unmask occlusive disease not apparent on resting studies. Exercise testing is a sensitive method for evaluating patients with symptoms suggestive of arterial obstruction when the resting extremity systolic pressures are normal.",
"   </p>",
"   <p>",
"    Exercise testing is most commonly performed to evaluate lower extremity peripheral artery disease (PAD). Exercise testing is generally not needed to diagnose upper extremity arterial disease, though, on occasion, it may play a role in the evaluation of subclavian steal syndrome. The discussion below focuses on lower extremity exercise testing. The principles of testing are the same for the upper extremity, except that a tabletop arm ergometer (hand crank) is used instead of a treadmill.",
"   </p>",
"   <p>",
"    The dynamics of blood flow across a stenotic lesion depend upon the severity of the obstruction and whether the individual is at rest or exercising. Exercise normally increases systolic pressure and decreases peripheral vascular resistance. The effects of exercise on the cardiovascular system are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise augments the pressure gradient across a stenotic lesion. An arterial stenosis less than 70 percent may not be sufficient to alter blood flow or produce a systolic pressure gradient at rest; however, following exercise, a moderate stenosis may be unmasked and the augmented gradient reflected as a reduction from the resting ankle-brachial index (ABI) following exercise. Repeat ABIs demonstrate a recovery to the resting, baseline ABI value over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68985486\">",
"    <span class=\"h3\">",
"     Protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many protocols for treadmill testing including fixed routines, graded routines and alternative protocols for patients with limited exercise ability [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With a fixed routine, patients are exercised with the treadmill at a constant speed with no change in the incline of the treadmill over the course of the study. A common fixed protocol involves walking on the treadmill at 2 mph at a 12 percent incline for five minutes or until the patient is forced to stop due to pain (not due to SOB or angina). The walking distance, time to the onset of pain, and nature of any symptoms are recorded. The ABI is recorded at rest, one minute after exercise, and every minute thereafter (up to 5 minutes) until it returns to the level of the resting ABI. The ABI in patients with severe disease may not return to baseline within the allotted time period.",
"     </li>",
"     <li>",
"      Graded routines may increase the speed of the treadmill, but more typically the percent incline of the treadmill is increased during the study. A metaanalysis of eight studies compared continuous versus graded routines in 658 patients in whom testing was repeated several times [",
"      <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/37\">",
"       37",
"      </a>",
"      ]. The estimated reliability in determining the intermittent claudication distance (initial distance to calf pain) and absolute claudication distance (patient can no longer walk) as assessed by the intraclass correlation coefficient was found to be significantly better for the graded protocol for absolute but not intermittent claudication distance. The reliability of a continuous protocol using a 12 percent grade approached the reliability of the graded protocol.",
"     </li>",
"     <li>",
"      For patients with limited exercise ability, alternative forms of exercise can be used. Plantar flexion exercises or &ldquo;toe ups&rdquo; involve having the patient stand on a block and raise onto the balls of the feet to exercise the calf muscles. This form of exercise has been verified against treadmill testing as accurate for detecting claudication and PAD.",
"     </li>",
"     <li>",
"      For patients who cannot exercise, reactive hyperemia testing or the administration of pharmacologic agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"       papaverine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      are alternatives testing methods to imitate the physiologic effect of exercise (vasodilation) and unmask a significant stenosis. Reactive hyperemia testing involves placing a pneumatic cuff at the thigh level and inflating it to a supra-systolic pressure for three to five minutes. This produces ischemia and compensatory vasodilation distal to the cuff; however, the test is painful, and thus, it is not commonly used. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68985493\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal response to exercise is a slight increase or no change in the ABI compared with baseline. If the patient develops symptoms with walking on the treadmill and does not have a corresponding decrease in ankle pressure, arterial obstruction as the cause of symptoms is essentially ruled out and the clinician should seek other causes for the leg symptoms.",
"   </p>",
"   <p>",
"    A fall in ankle systolic pressure by more than 20 percent from its baseline value, or below an absolute pressure of 60 mmHg that requires &gt;3 minutes to recover is considered abnormal. Severe claudication can be defined as an inability to complete the treadmill exercise due to leg symptoms and post-exercise ankle systolic pressures below 50 mmHg. Single-level disease is inferred with a recovery time that is &lt;6 minutes, while a &ge;6 minute recovery time is associated with multilevel disease, particularly a combination of supra-inguinal and infrainguinal occlusive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58550072\">",
"    <span class=\"h1\">",
"     TRANSCUTANEOUS OXYGEN MEASUREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcutaneous oxygen measurement (TcPO",
"    <sub>",
"     2",
"    </sub>",
"    ) may provide supplemental information regarding local tissue perfusion and the values have been used to assess the healing potential of lower extremity ulcers or amputation sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link\">",
"     \"Basic principles of wound management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23225?source=see_link\">",
"     \"Techniques for lower extremity amputation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Platinum oxygen electrodes are placed on the chest wall and legs or feet. The absolute value of the oxygen tension at the foot or leg, or a ratio of the foot value to chest wall value can be used. A normal value at the foot is 60 mmHg and a normal",
"    <span class=\"nowrap\">",
"     chest/foot",
"    </span>",
"    ratio is 0.9 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Local edema, skin temperature, emotional state (sympathetic vasoconstriction), inflammation, and pharmacologic agents limit the accuracy of the test.",
"   </p>",
"   <p>",
"    The level of TcPO",
"    <sub>",
"     2",
"    </sub>",
"    that indicates tissue healing remains controversial. It is generally accepted that in the absence of diabetes and tissue edema, wounds are likely to heal if oxygen tension is greater than 40 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/40\">",
"     40",
"    </a>",
"    ]. A higher value is needed for healing a foot ulcer in the patient with diabetes. Patients with values of &lt;20 mmHg are severely ischemic and are likely to need revascularization for wound healing. A metaanalysis of four studies found a more than threefold risk of developing a chronic wound healing complication in patients with a TcPO",
"    <sub>",
"     2",
"    </sub>",
"    below a threshold of 20 to 30 mmHg (odds ratio 3.26, 95% CI 1.07-9.69) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58544718\">",
"    <span class=\"h1\">",
"     ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound is the mainstay for noninvasive vascular imaging with each mode (eg, B-mode, duplex) providing specific information. Ultrasonography is used to evaluate the location and extent of vascular disease, arterial hemodynamics, and lesion morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Real-time ultrasonography uses reflected sound waves (echoes) to produce images and assess blood velocity. Two ultrasound modes are routinely used in vascular imaging: the B (brightness) mode and the Doppler mode (B mode imaging + Doppler flow detection = duplex ultrasound). Duplex ultrasonography has gained a prominent role in the noninvasive assessment of the peripheral vasculature overcoming the limitations (need for intravenous contrast) of other noninvasive methods and providing precise anatomic localization and accurate grading of lesion severity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both B-mode and Doppler mode take advantage of pulsed sound waves. Pulsed-wave technology uses a row of crystals, each of which alternately send and receive pulse trains of sound waves with a slight time delay with respect to their adjacent crystals. The time and intensity differences of the transmitted and received sound waves are converted to an image that displays depth and intensity for each crystal in the row. A pulse Doppler also permits localization of Doppler shifts induced by moving objects (red blood cells).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58549051\">",
"    <span class=\"h2\">",
"     Continuous wave Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;A continuous wave Doppler continually transmits and receives sound waves and, therefore, it cannot be used for imaging or to identify Doppler shifts. It is used primarily for blood pressure measurement (",
"    <a class=\"graphic graphic_picture graphicRef76440 \" href=\"UTD.htm?34/24/35203\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H58544655\">",
"     'Ankle-brachial index'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H58549402\">",
"     'Wrist-brachial index'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H58544690\">",
"     'Segmental pressures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The continuous wave hand-held ultrasound probe uses two separate ultrasound crystals, one for sending and one for receiving sound waves. Continuous wave ultrasound provides a signal that is a summation of all the vascular structures through which the sound has passed and is limited in the evaluation of a specific vascular structure when multiple vessels are present. However, the intensity and quality of the continuous wave Doppler signal can give an indication of the severity of vascular disease proximal to the probe. The quality of the arterial signal can be described as triphasic (like the heartbeat), biphasic (bum-bum), or monophasic.",
"   </p>",
"   <p>",
"    Biphasic signals may be normal in patients older than 60 because of decreased peripheral vascular resistance; however, monophasic signals unquestionably indicate significant pathology. Monophasic signals must be distinguished from venous signals, which vary with respiration and increase in intensity when the surrounding musculature is compressed (augmentation). It is often quite difficult to obtain ankle-brachial index values in patients with monophasic continuous wave Doppler signals. (See",
"    <a class=\"local\" href=\"#H58544655\">",
"     'Ankle-brachial index'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58548982\">",
"    <span class=\"h2\">",
"     B-mode imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The B-mode provides a grey scale image useful for evaluating anatomic detail (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65760 \" href=\"UTD.htm?11/43/11952\">",
"     image 1",
"    </a>",
"    ). The quality of a B-mode image depends upon the strength of the returning sound waves (echoes). Echo strength is attenuated and scattered as the sound wave moves through tissue. Angles of insonation of 90�� maximize the potential return of echoes. Higher frequency sound waves provide better lateral resolution compared with lower frequency waves. Thus, high-frequency transducers are used for imaging shallow structures at 90�� of insonation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58548990\">",
"    <span class=\"h2\">",
"     Duplex imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplex scanning can be used to evaluate the vasculature preoperatively, intraoperatively, and postoperatively for stent or graft surveillance and is very useful in identifying proximal arterial disease. A meta-analysis of 14 studies found that sensitivity and specificity of this technique for &ge;50 percent stenosis or occlusion were 86 and 97 percent for aortoiliac disease and 80 and 98 percent for femoropopliteal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The identification of vascular structures from the B-mode display is enhanced in the color mode, which displays movement (blood flow) within the field (",
"    <a class=\"graphic graphic_waveform graphicRef82357 \" href=\"UTD.htm?27/56/28547\">",
"     waveform 1",
"    </a>",
"    ). The shift in sound frequency between the transmitted and received sound waves due to movement of red blood cells is analyzed to generate velocity information (Doppler mode). Flow toward the transducer is standardized to display as red and flow away from the transducer is blue; the colors are semi-quantitative and do not represent actual arterial or venous flow.",
"   </p>",
"   <p>",
"    Accurate measurements of Doppler shift and, therefore, velocity measurements require proper positioning of the ultrasound probe relative to the direction of flow. An angle of insonation of sixty degrees is ideal; however, an angle between 30&deg; and 70&deg; is acceptable. The severity of stenosis is best assessed by positioning the Doppler probe directly over the lesion. The ratio of the velocity of blood at a suspected stenosis to the velocity obtained in a normal portion of the vessel is calculated. Velocity ratios &gt;4.0 indicate a &gt;75 percent stenosis in peripheral arteries (",
"    <a class=\"graphic graphic_table graphicRef80574 \" href=\"UTD.htm?2/59/3003\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A normal arterial Doppler velocity waveform is triphasic with a sharp upstroke, forward flow in systole with a sharp systolic peak, sharp downstroke, reversed flow component at the end of systole, and forward flow in late diastole (",
"    <a class=\"graphic graphic_waveform graphicRef61122 \" href=\"UTD.htm?4/25/4496\">",
"     waveform 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The spectral band is narrow and a characteristic lucent spectral window can be seen between the upstroke and downstroke (",
"    <a class=\"graphic graphic_waveform graphicRef82357 \" href=\"UTD.htm?27/56/28547\">",
"     waveform 1",
"    </a>",
"    ). Normal velocities vary with the artery examined and decrease as one proceeds more distally in an extremity (",
"    <a class=\"graphic graphic_table graphicRef61562 \" href=\"UTD.htm?4/34/4651\">",
"     table 2",
"    </a>",
"    ). For example, velocities in the iliac artery vary between 100 and 200",
"    <span class=\"nowrap\">",
"     cm/s",
"    </span>",
"    and peak systolic velocities in the tibial artery are 40 and 70",
"    <span class=\"nowrap\">",
"     cm/s.",
"    </span>",
"   </p>",
"   <p>",
"    Different velocity waveforms are obtained depending upon whether the probe is proximal or distal to a stenosis. Progressive obstruction proximal to the Doppler probe results in a decrease in systolic peak, elimination of the reversed flow component and an increase in the flow seen in late diastole. Decreased peripheral vascular resistance is responsible for the loss of the reversed flow component and this finding may be normal in older patients or reflect compensatory vasodilation in response to an obstructive vascular lesion.",
"   </p>",
"   <p>",
"    A delayed upstroke, blunted peak, and no second component signify progressive obstruction proximal to the probe (",
"    <a class=\"graphic graphic_waveform graphicRef53869 \" href=\"UTD.htm?20/4/20559\">",
"     waveform 3",
"    </a>",
"    ), and a flat waveform indicates severe obstruction.",
"   </p>",
"   <p>",
"    The pitch of the duplex signal changes in proportion to the velocity of the blood with high-pitched harsh sounds indicative of stenosis. Proximal to a high-grade stenosis with minimal compensatory collateralization, a thumping sound is heard.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58551139\">",
"    <span class=\"h3\">",
"     Specific anatomic sites",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Aortoiliac",
"      </strong>",
"      &ndash; Aortoiliac imaging requires the patient to fast for about 12 hours to reduce interference by bowel gas. It is therefore most convenient to obtain these studies early in the morning. Satisfactory aortoiliac Doppler signals (",
"      <a class=\"graphic graphic_waveform graphicRef61716 \" href=\"UTD.htm?15/38/15969\">",
"       waveform 4",
"      </a>",
"      ) can be obtained from approximately 90 percent of individuals who have been properly prepared. Complete examination involves the visceral aorta, iliac bifurcation, and iliac arteries distally.",
"     </li>",
"     <li>",
"      <strong>",
"       Extremities",
"      </strong>",
"      &ndash; For the lower extremity, examination begins at the common femoral artery and is routinely carried through the popliteal artery. The tibial arteries can also be evaluated. In the upper extremities, the extent of the examination is determined by the clinical indication. Visualization of the subclavian artery is limited by the clavicle.",
"      <br/>",
"      <br/>",
"      Any areas of stenosis are initially localized with color Doppler and then quantified and assessed by measuring Doppler velocities. In general, the ratio of the peak systolic velocity (PSV) within an area of stenosis is compared with the PSV in the vessel just proximal to it to estimate the degree of stenosis. For the lower extremity, the percent stenosis can be estimated. A PSV ratio that is 1.5 to 2.0 indicates a 50 percent arterial stenosis and a ratio &gt;4.0 indicates &gt;75 percent stenosis (",
"      <a class=\"graphic graphic_table graphicRef80574 \" href=\"UTD.htm?2/59/3003\">",
"       table 1",
"      </a>",
"      ). The same general principles apply when determining the degree of stenosis within a lower extremity bypass graft.",
"      <br/>",
"      <br/>",
"      There are no generally agreed upon criteria for determining stenosis in upper extremity arteries, and most vascular laboratories tend to extrapolate criteria from lower extremity arteries to upper extremity arteries.",
"     </li>",
"     <li>",
"      <strong>",
"       Visceral arteries",
"      </strong>",
"      &ndash; Duplex examination of visceral arteries, especially the renal arteries, requires the use of low frequency transducers to penetrate to the depth of these vessels. Fasting is required prior to examination to minimize overlying bowel gas. Validated velocity criteria for determining the degree of stenosis in visceral vessels are given in the table (",
"      <a class=\"graphic graphic_table graphicRef76874 \" href=\"UTD.htm?33/12/33995\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58544732\">",
"    <span class=\"h1\">",
"     OTHER IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast arteriography remains the gold standard for vascular imaging and, under some circumstances (eg, acute ischemia), is the primary imaging modality because it offers the benefit of potential simultaneous intervention. However, because arteriography exposes the patient to radiation and other complications associated with percutaneous arterial access and iodinated contrast, other modalities including computed tomography and magnetic resonance imaging have become important alternative methods for vascular assessment.",
"   </p>",
"   <p>",
"    The development of multidetector computed tomography (MDCT) allows rapid acquisition of high resolution, contrast-enhanced arterial images [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. However, the examination is expensive and also involves radiation exposure and the intravenous contrast agents. A meta-analysis of 20 studies in which MDCT was used to evaluate 19,092 lower extremity arterial segments in 957 symptomatic patients compared test performance with DSA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/50\">",
"     50",
"    </a>",
"    ]. The sensitivity and specificity for detecting a stenosis of &ge;50 percent with MDCT and DSA were 95 and 96 percent, respectively. Six studies evaluated diagnostic performance according to anatomic region of the arterial system. Arterial occlusions were correctly identified in 94 percent of segments and the absence of a significant stenosis correctly identified in 96 percent of segments. Specificity was lower in the tibial arteries compared with the aortoiliac and femoropopliteal segment, but the difference was not significant. MDCT has been used to guide the need for intervention. In a series of 58 patients with claudication, none of 29 patients in whom conservative management was indicated by MDCT required revascularization at a mean follow-up of 501 days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance angiography (MRA), using rapid three-dimensional imaging sequences combined with gadolinium contrast agents, has shown promise to become a time-efficient and cost-effective tool for the assessment of lower extremity peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/16/10506/abstract/1,52-54\">",
"     1,52-54",
"    </a>",
"    ]. MRA is usually only performed if revascularization is being considered. A potential, severe complication associated with use of gadolinium in patients with renal failure is nephrogenic systemic",
"    <span class=\"nowrap\">",
"     sclerosis/nephrogenic",
"    </span>",
"    fibrosing dermopathy, and therefore gadolinium is contraindicated in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link&amp;anchor=H4#H4\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'Gadolinium'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34578?source=see_link\">",
"       \"Patient information: Peripheral artery disease and claudication (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30242?source=see_link\">",
"       \"Patient information: Doppler ultrasound (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=see_link\">",
"       \"Patient information: Peripheral artery disease and claudication (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58544746\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninvasive vascular testing is an extension of the vascular history and physical examination and is used to confirm a diagnosis of arterial disease and determine the level and extent of disease. Available studies include physiologic tests that correlate symptoms with site and severity of arterial occlusive disease, and imaging studies that further delineate vascular anatomy. (See",
"      <a class=\"local\" href=\"#H58544613\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Noninvasive vascular testing may be indicated to screen patients with risk factors for arterial disease, establish a diagnosis in patients with symptoms or signs consistent with arterial disease, identify a vascular injury, or evaluate the vasculature preoperatively, intraoperatively, or for surveillance following a vascular procedure (eg, stent, bypass). (See",
"      <a class=\"local\" href=\"#H58544620\">",
"       'Indications for testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physiologic tests include segmental limb pressure measurements and the determination of pressure index values (eg, ankle-brachial index, wrist-brachial index, toe-brachial index), exercise testing, segmental volume plethysmography, and transcutaneous oxygen measurements. These tests generally correlate to clinical symptoms and are used to stratify the need for further evaluation and treatment. (See",
"      <a class=\"local\" href=\"#H58549369\">",
"       'Physiologic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The comparison of the resting systolic blood pressure at the ankle to the systolic brachial pressure is referred to as the ankle-brachial (ABI) index. The analogous index in the upper extremity is the wrist-brachial index (WBI). (See",
"      <a class=\"local\" href=\"#H58544655\">",
"       'Ankle-brachial index'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H58549402\">",
"       'Wrist-brachial index'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For the lower extremity:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      ABI of 0.91 to 1.30 is normal.",
"     </li>",
"     <li>",
"      ABI &le;0.90 is diagnostic of arterial obstruction.",
"     </li>",
"     <li>",
"      ABI &gt;1.30 suggests the presence of calcified vessels",
"     </li>",
"     <li>",
"      Further evaluation is dependent upon the ABI value (",
"      <a class=\"graphic graphic_algorithm graphicRef85752 graphicRef50445 \" href=\"UTD.htm?37/0/37903\">",
"       algorithm 1A-B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a normal ankle-brachial index (ABI) who have typical symptoms of claudication, we suggest exercise testing. An ABI that decreases by 20 percent following exercise is diagnostic of arterial obstruction whereas a normal ABI following exercise eliminates a diagnosis of arterial obstruction and suggests the need to seek other causes for the leg symptoms. (See",
"      <a class=\"local\" href=\"#H146789783\">",
"       'Exercise testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For symptomatic patients with an ABI &le;0.9 who are possible candidates for intervention, we perform additional noninvasive vascular studies to further define the level and extent of disease. Depending upon the clinical scenario, additional testing may include additional physiologic tests, duplex ultrasonography, or other imaging such as angiography using computed tomography or magnetic resonance imaging, or conventional arteriography. (See",
"      <a class=\"local\" href=\"#H58544655\">",
"       'Ankle-brachial index'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H58549369\">",
"       'Physiologic testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H58544718\">",
"       'Ultrasound'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H58544732\">",
"       'Other imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an ABI &gt;1.3, the toe-brachial index (TBI) and pulse volume recordings (PVRs) should be performed. A normal toe-brachial index is 0.7 to 0.8. The normal PVR waveform is composed of a systolic upstroke with a sharp systolic peak followed by a downstroke that contains a prominent dicrotic notch. Progressive obstruction alters the normal waveform and blunts its amplitude. (See",
"      <a class=\"local\" href=\"#H58544669\">",
"       'High ABI'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H58549539\">",
"       'Toe-brachial index'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H58544704\">",
"       'Pulse volume recordings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transcutaneous oxygen measurement may supplement other physiologic tests by providing information regarding local tissue perfusion. A normal value at the foot is 60 mmHg and a normal",
"      <span class=\"nowrap\">",
"       chest/foot",
"      </span>",
"      ratio is 0.9. (See",
"      <a class=\"local\" href=\"#H58550072\">",
"       'Transcutaneous oxygen measurements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a normal ankle- or wrist-brachial index and distal extremity ischemia, individual digit waveforms and digit pressures can be used to identify small vessel occlusive arterial disease. (See",
"      <a class=\"local\" href=\"#H86998053\">",
"       'Digit waveforms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound is routinely used for vascular imaging. B-mode imaging is the primary modality for evaluating and following aneurysmal disease, while duplex scanning is used to define the site and severity of vascular obstruction. Areas of stenosis localized with Doppler can be quantified by comparing the peak systolic velocity (PSV) within a narrowed area to the PSV in the vessel just proximal to it (PSV ratio). The percent stenosis in lower extremity native vessels and vascular grafts can be estimated (",
"      <a class=\"graphic graphic_table graphicRef80574 \" href=\"UTD.htm?2/59/3003\">",
"       table 1",
"      </a>",
"      ). A PSV ratio &gt;4.0 indicates a &gt;75 percent stenosis. These criteria can also be used for the upper extremity. Validated criteria for the visceral vessels are given in the table (",
"      <a class=\"graphic graphic_table graphicRef76874 \" href=\"UTD.htm?33/12/33995\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H58544718\">",
"       'Ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contrast arteriography remains the gold standard for vascular imaging and, under some circumstances (eg, acute ischemia), is the primary imaging modality because it offers the benefit of potential simultaneous intervention. Other imaging modalities include multidetector computed tomography (MDCT) and magnetic resonance imaging and angiography (MRA). (See",
"      <a class=\"local\" href=\"#H58544732\">",
"       'Other imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/1\">",
"      Spittell JA Jr. Diagnosis and management of occlusive peripheral arterial disease. Curr Probl Cardiol 1990; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/2\">",
"      Rofsky NM, Adelman MA. MR angiography in the evaluation of atherosclerotic peripheral vascular disease. Radiology 2000; 214:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/3\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/4\">",
"      Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/5\">",
"      Leng GC, Fowkes FG, Lee AJ, et al. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996; 313:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/6\">",
"      O'Hare AM, Katz R, Shlipak MG, et al. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 2006; 113:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/7\">",
"      Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/8\">",
"      American Diabetes Association. Standards of medical care in diabetes--2008. Diabetes Care 2008; 31 Suppl 1:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/9\">",
"      PASCARELLI EF, BERTRAND CA. COMPARISON OF BLOOD PRESSURES IN THE ARMS AND LEGS. N Engl J Med 1964; 270:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/10\">",
"      Olin JW, Kaufman JA, Bluemke DA, et al. Atherosclerotic Vascular Disease Conference: Writing Group IV: imaging. Circulation 2004; 109:2626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/11\">",
"      Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003; 163:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/12\">",
"      Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/13\">",
"      Mohler ER 3rd. Peripheral arterial disease: identification and implications. Arch Intern Med 2003; 163:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/14\">",
"      Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/15\">",
"      Wolf EA Jr, Sumner DS, Strandness DE Jr. Correlation between nutritive blood flow and pressure in limbs of patients with intermittent claudication. Surg Forum 1972; 23:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/16\">",
"      McDermott MM, Greenland P, Liu K, et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 2002; 136:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/17\">",
"      McDermott MM, Ferrucci L, Guralnik JM, et al. The ankle-brachial index is associated with the magnitude of impaired walking endurance among men and women with peripheral arterial disease. Vasc Med 2010; 15:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/18\">",
"      Wang JC, Criqui MH, Denenberg JO, et al. Exertional leg pain in patients with and without peripheral arterial disease. Circulation 2005; 112:3501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/19\">",
"      McPhail IR, Spittell PC, Weston SA, Bailey KR. Intermittent claudication: an objective office-based assessment. J Am Coll Cardiol 2001; 37:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/20\">",
"      Kuller LH, Shemanski L, Psaty BM, et al. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation 1995; 92:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/21\">",
"      Vogt MT, Cauley JA, Newman AB, et al. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993; 270:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/22\">",
"      Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004; 109:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/23\">",
"      Murabito JM, Evans JC, Larson MG, et al. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med 2003; 163:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/24\">",
"      O'Hare AM, Rodriguez RA, Bacchetti P. Low ankle-brachial index associated with rise in creatinine level over time: results from the atherosclerosis risk in communities study. Arch Intern Med 2005; 165:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/25\">",
"      Bund&oacute; M, Mu&ntilde;oz L, P&eacute;rez C, et al. Asymptomatic peripheral arterial disease in type 2 diabetes patients: a 10-year follow-up study of the utility of the ankle brachial index as a prognostic marker of cardiovascular disease. Ann Vasc Surg 2010; 24:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/26\">",
"      Resnick HE, Foster GL. Prevalence of elevated ankle-brachial index in the United States 1999 to 2002. Am J Med 2005; 118:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/27\">",
"      Ix JH, Katz R, Peralta CA, et al. A high ankle brachial index is associated with greater left ventricular mass MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010; 55:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/28\">",
"      Carter SA, Tate RB. Value of toe pulse waves in addition to systolic pressures in the assessment of the severity of peripheral arterial disease and critical limb ischemia. J Vasc Surg 1996; 24:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/29\">",
"      Vitti MJ, Robinson DV, Hauer-Jensen M, et al. Wound healing in forefoot amputations: the predictive value of toe pressure. Ann Vasc Surg 1994; 8:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/30\">",
"      Apelqvist J, Castenfors J, Larsson J, et al. Prognostic value of systolic ankle and toe blood pressure levels in outcome of diabetic foot ulcer. Diabetes Care 1989; 12:373.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.iwgdf.org/index.php?option=com_content&amp;task=view&amp;id=43&amp;Itemid=63 (Accessed on June 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/32\">",
"      Heintz SE, Bone GE, Slaymaker EE, et al. Value of arterial pressure measurements in the proximal and distal part of the thigh in arterial occlusive disease. Surg Gynecol Obstet 1978; 146:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/33\">",
"      Sumner DS, Strandness DE Jr. The relationship between calf blood flow and ankle blood pressure in patients with intermittent claudication. Surgery 1969; 65:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/34\">",
"      Darling RC, Raines JK, Brener BJ, Austen WG. Quantitative segmental pulse volume recorder: a clinical tool. Surgery 1972; 72:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/35\">",
"      Kempczinski RF. Segmental volume plethysmography in the diagnosis of lower extremity arterial occlusive disease. J Cardiovasc Surg (Torino) 1982; 23:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/36\">",
"      Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation 1995; 92:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/37\">",
"      Nicola&iuml; SP, Viechtbauer W, Kruidenier LM, et al. Reliability of treadmill testing in peripheral arterial disease: a meta-regression analysis. J Vasc Surg 2009; 50:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/38\">",
"      Bowers BL, Valentine RJ, Myers SI, et al. The natural history of patients with claudication with toe pressures of 40 mm Hg or less. J Vasc Surg 1993; 18:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/39\">",
"      Byrne P, Provan JL, Ameli FM, Jones DP. The use of transcutaneous oxygen tension measurements in the diagnosis of peripheral vascular insufficiency. Ann Surg 1984; 200:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/40\">",
"      Arsenault KA, McDonald J, Devereaux PJ, et al. The use of transcutaneous oximetry to predict complications of chronic wound healing: a systematic review and meta-analysis. Wound Repair Regen 2011; 19:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/41\">",
"      Moneta GL, Yeager RA, Lee RW, Porter JM. Noninvasive localization of arterial occlusive disease: a comparison of segmental Doppler pressures and arterial duplex mapping. J Vasc Surg 1993; 17:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/42\">",
"      AbuRahma AF, Khan S, Robinson PA. Selective use of segmental Doppler pressures and color duplex imaging in the localization of arterial occlusive disease of the lower extremity. Surgery 1995; 118:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/43\">",
"      Koelemay MJ, den Hartog D, Prins MH, et al. Diagnosis of arterial disease of the lower extremities with duplex ultrasonography. Br J Surg 1996; 83:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/44\">",
"      Kohler TR, Nance DR, Cramer MM, et al. Duplex scanning for diagnosis of aortoiliac and femoropopliteal disease: a prospective study. Circulation 1987; 76:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/45\">",
"      Zierler RE. Duplex and color-flow imaging of the lower extremity arterial circulation. Semin Ultrasound CT MR 1990; 11:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/46\">",
"      Ota H, Takase K, Igarashi K, et al. MDCT compared with digital subtraction angiography for assessment of lower extremity arterial occlusive disease: importance of reviewing cross-sectional images. AJR Am J Roentgenol 2004; 182:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/47\">",
"      Romano M, Mainenti PP, Imbriaco M, et al. Multidetector row CT angiography of the abdominal aorta and lower extremities in patients with peripheral arterial occlusive disease: diagnostic accuracy and interobserver agreement. Eur J Radiol 2004; 50:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/48\">",
"      Adriaensen ME, Kock MC, Stijnen T, et al. Peripheral arterial disease: therapeutic confidence of CT versus digital subtraction angiography and effects on additional imaging recommendations. Radiology 2004; 233:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/49\">",
"      Edwards AJ, Wells IP, Roobottom CA. Multidetector row CT angiography of the lower limb arteries: a prospective comparison of volume-rendered techniques and intra-arterial digital subtraction angiography. Clin Radiol 2005; 60:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/50\">",
"      Met R, Bipat S, Legemate DA, et al. Diagnostic performance of computed tomography angiography in peripheral arterial disease: a systematic review and meta-analysis. JAMA 2009; 301:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/51\">",
"      Schernthaner R, Fleischmann D, Lomoschitz F, et al. Effect of MDCT angiographic findings on the management of intermittent claudication. AJR Am J Roentgenol 2007; 189:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/52\">",
"      Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/53\">",
"      McDermott MM, Kerwin DR, Liu K, et al. Prevalence and significance of unrecognized lower extremity peripheral arterial disease in general medicine practice*. J Gen Intern Med 2001; 16:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/16/10506/abstract/54\">",
"      Menke J, Larsen J. Meta-analysis: Accuracy of contrast-enhanced magnetic resonance angiography for assessing steno-occlusions in peripheral arterial disease. Ann Intern Med 2010; 153:325.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8201 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-4874105216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10506=[""].join("\n");
var outline_f10_16_10506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H58544746\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58544613\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58544620\">",
"      INDICATIONS FOR TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58549369\">",
"      PHYSIOLOGIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58544655\">",
"      Ankle-brachial index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58544669\">",
"      - High ABI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58549402\">",
"      Wrist-brachial index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58549539\">",
"      Toe-brachial index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58544690\">",
"      Segmental pressures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H146789823\">",
"      - Lower extremity segmental pressures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H146789830\">",
"      - Upper extremity segmental pressures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58544704\">",
"      Pulse volume recordings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86998053\">",
"      - Digit waveforms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H146789783\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H68985486\">",
"      - Protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H68985493\">",
"      - Interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58550072\">",
"      TRANSCUTANEOUS OXYGEN MEASUREMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58544718\">",
"      ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58549051\">",
"      Continuous wave Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58548982\">",
"      B-mode imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58548990\">",
"      Duplex imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58551139\">",
"      - Specific anatomic sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58544732\">",
"      OTHER IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58544746\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8201\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8201|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/57/31645\" title=\"algorithm 1A\">",
"      Algorithm for vascular testing in asymptomatic PAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?32/53/33630\" title=\"algorithm 1B\">",
"      Algorithm for vascular testing in symptomatic PAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8201|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/43/11952\" title=\"diagnostic image 1\">",
"      Ultrasound of popliteal artery aneursym",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8201|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/13/9429\" title=\"figure 1\">",
"      Normal and abnormal plethysmographic digit waveforms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/1/43033\" title=\"figure 2\">",
"      Segmental pressure examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/19/3386\" title=\"figure 3\">",
"      Upper extremity arm pressures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8201|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/24/35203\" title=\"picture 1\">",
"      Bi-directional Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/23/33137\" title=\"picture 2\">",
"      Four cuff segmental pressures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/33/36381\" title=\"picture 3\">",
"      Pulse volume recordings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8201|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/59/3003\" title=\"table 1\">",
"      Peak systolic velocity ratios arterial duplex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/34/4651\" title=\"table 2\">",
"      Normal arterial Doppler velocities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/12/33995\" title=\"table 3\">",
"      Validated criteria for stenosis in visceral vessels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8201|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?27/56/28547\" title=\"waveform 1\">",
"      Doppler waveform within stented artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?4/25/4496\" title=\"waveform 2\">",
"      Normal arterial Doppler waveform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?20/4/20559\" title=\"waveform 3\">",
"      Monophasic arterial Doppler waveform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?15/38/15969\" title=\"waveform 4\">",
"      Aorta Doppler waveform",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/266?source=related_link\">",
"      Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33206?source=related_link\">",
"      Chronic mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=related_link\">",
"      Clinical manifestations and evaluation of chronic critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37210?source=related_link\">",
"      Creating an arteriovenous fistula for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=related_link\">",
"      Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=related_link\">",
"      Overview of thoracic outlet syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12245?source=related_link\">",
"      Overview of upper extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30242?source=related_link\">",
"      Patient information: Doppler ultrasound (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34578?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38921?source=related_link\">",
"      Percutaneous interventional procedures in the patient with lower extremity claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3065?source=related_link\">",
"      Popliteal artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24488?source=related_link\">",
"      Screening for abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34361?source=related_link\">",
"      Screening for asymptomatic carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24200?source=related_link\">",
"      Screening for lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12186?source=related_link\">",
"      Severe extremity injury in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23225?source=related_link\">",
"      Techniques for lower extremity amputation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_16_10507="Units of alcohol";
var content_f10_16_10507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Units of alcohol",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Beverage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Quantity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of units*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beers and lagers",
"       </td>",
"       <td>",
"        1 pint (560 mls)",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wine",
"       </td>",
"       <td>",
"        125 ml glass",
"       </td>",
"       <td>",
"        1 to 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spirits",
"       </td>",
"       <td>",
"        1/6th gill",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cider",
"       </td>",
"       <td>",
"        1 pint (560 mls)",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sherry/port",
"       </td>",
"       <td>",
"        1 glass",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * 1 unit contains approximately 8 g of alcohol.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ihsan Rafie, MRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10507=[""].join("\n");
var outline_f10_16_10507=null;
var title_f10_16_10508="Physical causes anxiety Sxs";
var content_f10_16_10508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical causes of anxiety-like symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angina pectoris, arrhythmias, heart failure, hypertension, hypovolemia, myocardial infarction, syncope (multiple causes), valvular disease, vascular collapse (shock)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Dietary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caffeine, monosodium glutamate (Chinese restaurant syndrome), vitamin-deficiency diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drug-related",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Akathisia (secondary to antipsychotic drugs), anticholinergic toxicity, digitalis toxicity, hallucinogens, hypotensive agents, stimulants (amphetamines, cocaine, related drugs), withdrawal syndromes (alcohol, sedative-hypnotics), bronchodilators (theophylline, sympathomimetics)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hematologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaphylaxis, systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperadrenalism (Cushing's disease), hyperkalemia, hyperthermia, hyperthyroidism, hypocalcemia, hypoglycemia, hyponatremia, hypothyroidism, menopause, porphyria (acute intermittent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalopathies (infectious, metabolic, toxic), essential tremor, intracranial mass lesions, postconcussive syndrome, seizure disorders (especially of the temporal lobe), vertigo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Respiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma, chronic obstructive pulmonary disease, pneumonia, pneumothorax, pulmonary edema, pulmonary embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Secreting tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carcinoid, insulinoma, pheochromocytoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Rosenbaum, JF, N Engl J Med 1982; 306:401.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10508=[""].join("\n");
var outline_f10_16_10508=null;
var title_f10_16_10509="Dry powder inhaler technique II";
var content_f10_16_10509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Technique for use of various dry powder inhalers - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        HandiHaler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capsules should be stored in sealed blisters and only removed immediately before use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peel back the foil using the tab until one capsule is fully visible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Open the dust cap by pulling it upwards, then open the mouthpiece.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place the capsule in the center chamber (it does not matter which end of the capsule is placed in the chamber).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Close the mouthpiece firmly until you hear a click, leaving the dust cap open.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hold the HandiHaler with the mouthpiece upwards and press the piercing button completely in once and release.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe out completely. Do not breathe into the mouthpiece at any time.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Close your lips tightly around the mouthpiece.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe in rapidly and steadily, as deeply as possible; hold breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To ensure you get the full dose, repeat the inhalation from the HandiHaler as described.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        After the dose, open the mouthpiece, tip out the used capsule, and dispose. Do not handle used capsules.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Close the mouthpiece and dust cap for storage; store device in cool, dry place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Turbuhaler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Twist and remove cover.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hold inhaler upright with mouthpiece facing up.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Turn grip right then left until it clicks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhaler may be held upright or horizontal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe in rapidly and steadily, as deeply as possible; hold breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove device from mouth and exhale outside device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace cover and twist to close; store device in cool, dry place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Twisthaler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hold the inhaler straight up with the pink portion (the base) on the bottom.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove the cap while it is in the upright position to make sure you get the right amount of medicine with each dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hold the pink base and twist the cap in a counter-clockwise direction to remove it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        As you lift off the cap, the dose counter on the base will count down by 1. This action loads the medicine that you are now ready to inhale.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make sure the indented arrow located on the white portion (directly above the pink base) is pointing to the dose counter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe out normally - do not exhale into the device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place the mouthpiece into your mouth, with the mouthpiece facing towards you, and close your lips tightly around it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhale dose with a rapid and steady flow while holding the Twisthaler horizontal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove the mouthpiece from your mouth and hold your breath for 5 to 10 seconds (or as long as you comfortably can).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When you exhale, be sure that you are not exhaling into the device",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immediately replace the cap and turn in a clockwise direction as you gently press down until you hear a click.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Firmly close the Twisthaler to assure that your next dose is properly loaded.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Be sure that the arrow is in line with the dose-counter window.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Store device in cool dry place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The dose counter displays the number of doses remaining. When the unit reads 01, this indicates the last remaining dose. When the counter reads 00, the unit must then be discarded.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10509=[""].join("\n");
var outline_f10_16_10509=null;
var title_f10_16_10510="Fungal otitis externa";
var content_f10_16_10510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fungal otitis externa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    External auditory canal with purulent debris coated with fungal filaments and spores.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laura A Goguen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_16_10510=[""].join("\n");
var outline_f10_16_10510=null;
var title_f10_16_10511="Contents: Pediatric rheumatology";
var content_f10_16_10511=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric rheumatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric rheumatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Chronic pain syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/45/7896\">",
"           Clinical manifestations and diagnosis of fibromyalgia in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/56/37768\">",
"           Complex regional pain syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/26/20902\">",
"           Growing pains",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/57/19350\">",
"           Treatment and prognosis of fibromyalgia in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatomyositis and polymyositis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/22/31079\">",
"           Diagnosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29368\">",
"           Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/5/2138\">",
"           Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33383\">",
"           Approach to evaluating childhood vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2679\">",
"           Evaluation of the child with back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/46/14057\">",
"           Evaluation of the child with joint pain or swelling",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Joint aspiration",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/47/21239\">",
"           Joint aspiration or injection in children: Indications, technique, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/31/28148\">",
"           Joint aspiration: The dry tap",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Juvenile arthritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/56/35717\">",
"           Classification of juvenile arthritis (JRA/JIA)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/3/39994\">",
"           Juvenile idiopathic arthritis: Epidemiology and immunopathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/15/41210\">",
"           Pathogenesis of rheumatoid arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/31/24056\">",
"           Pauciarticular onset juvenile idiopathic arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/25/24983\">",
"           Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/48/17162\">",
"           Polyarticular onset juvenile idiopathic arthritis: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/6/12390\">",
"           Psoriatic juvenile idiopathic arthritis: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/40/40584\">",
"           Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/31/8696\">",
"           Spondyloarthropathy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21046\">",
"           Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/23/39285\">",
"           Systemic onset juvenile idiopathic arthritis: Course, prognosis, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/9/5274\">",
"           Systemic onset juvenile idiopathic arthritis: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Kawasaki disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/34/11814\">",
"           Incomplete (atypical) Kawasaki disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/61/12248\">",
"           Kawasaki disease: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/51/16183\">",
"           Kawasaki disease: Complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/19/11575\">",
"           Kawasaki disease: Epidemiology and etiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/2/42025\">",
"           Kawasaki disease: Initial treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/52/40775\">",
"           Treatment of refractory Kawasaki disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Metabolic myopathies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/56/905\">",
"           Approach to the metabolic myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/36/21065\">",
"           Causes of metabolic myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/63/6134\">",
"           Energy metabolism in muscle",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Office orthopedics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/45/19162\">",
"           Back pain in children and adolescents: Overview of causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2679\">",
"           Evaluation of the child with back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/21/16729\">",
"           Overview of hip pain in childhood",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/58/24487\">",
"           Cryopyrin-associated periodic syndromes and related disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/8/15494\">",
"           Periodic fever syndromes and other autoinflammatory diseases: An overview",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathogenesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/14/6376\">",
"           Pathogenesis of sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/63/19450\">",
"           Pathogenesis of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23719\">",
"           Pathogenesis of the Raynaud phenomenon",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rheumatic fever",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/20/23879\">",
"           Clinical manifestations and diagnosis of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/8/8327\">",
"           Epidemiology and pathogenesis of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/31/22007\">",
"           Sydenham chorea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/2/44070\">",
"           Treatment and prevention of acute rheumatic fever",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Scleroderma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/32/39433\">",
"           Juvenile systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/1/40985\">",
"           Localized scleroderma in childhood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/63/19450\">",
"           Pathogenesis of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sj&ouml;gren's syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/22/18794\">",
"           Classification and diagnosis of Sj������gren's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/1/11287\">",
"           Clinical manifestations of Sj������gren's syndrome: Exocrine gland disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/42/27306\">",
"           Clinical manifestations of Sj������gren's syndrome: Extraglandular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/36/25162\">",
"           Pathogenesis of Sj������gren's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/11/44212\">",
"           Patient information: Sj������gren���������s syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/12/26826\">",
"           Treatment of dry eyes in Sj������gren's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/57/36762\">",
"           Treatment of dry mouth and other non-ocular sicca symptoms in Sj������gren's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/14/2282\">",
"           Treatment of systemic and extraglandular manifestations of Sj������gren���������s syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Systemic lupus erythematosus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/12/31943\">",
"           Cardiac abnormalities in children and adolescents with systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/42/27303\">",
"           Hematologic problems in children and adolescents with systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/57/24474\">",
"           Neonatal lupus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/34/42534\">",
"           Pulmonary manifestations of systemic lupus erythematosus in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/35/10810\">",
"           Systemic lupus erythematosus in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vasculitides",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33383\">",
"           Approach to evaluating childhood vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40616\">",
"           Classification and incidence of childhood vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/49/40729\">",
"           Clinical manifestations and diagnosis of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/62/4070\">",
"           Hypersensitivity vasculitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28646\">",
"           Management of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/27/9657\">",
"           Overview of the management of vasculitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/54/5993\">",
"           Renal manifestations of Henoch-Sch������nlein purpura",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-05F35FA73D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_16_10511=[""].join("\n");
var outline_f10_16_10511=null;
